






THE ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR 2 











A dissertation submitted to Johns Hopkins University in conformity with the 
















 Current statistics for the incidence of breast cancer reveal that it is the most 
common form of cancer and leading cause of death from cancer among women 
worldwide. In the US, breast cancer follows lung cancer as the second largest cause of 
cancer mortality and is the most common type of cancer in American women. 
Approximately 15-20% of breast cancers are characterized as HER2/neu/ErbB2 
(epidermal growth factor receptor 2)-positive. The combination of doxorubicin and the 
ErbB2 inhibitor Herceptin/trastuzumab is efficacious against ErbB2-overexpressing 
breast cancer but has been shown to cause cardiotoxicity and has been linked to an 
increased risk for developing cardiac failure.  
 The following chapters of this dissertation will explore the intricacies of ErbB2 
tyrosine kinase signaling and the essential roles of ErbB2 in cardiac development and 
function. For our studies we employed a transgenic murine model of cardiac-specific 
ErbB2 overexpression developed in our lab that has concentric cardiac hypertrophy that 
does not progress to heart failure. Since oxidative stress mediates the transition from 
cardiac hypertrophy to heart failure, we sought to investigate the underlying mechanisms 
of ErbB2 overexpression on redox signaling pathways involved in antioxidant protection 
against reactive oxygen species (ROS). Indeed, hearts from the ErbB2 transgenic 
(ErbB2tg) mice and their cardiac mitochondria have lower levels of ROS. We proposed 
that ErbB2 regulates the Abelson nonreceptor tyrosine kinases to subsequently activate 
glutathione peroxidase (GPx) and reduce ROS levels. In vitro models of ErbB2 
overexpression and abrogration in the H9c2 rat cardiomyoblast cell line were developed 
to assess these associations. Studies with neonatal cardiomyocytes suggest that GPx 
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activity in the ErbB2tg mice is dependent upon the hypertrophic phenotype that is 
conspicuously absent in the H9c2 cells. 
 Using the ErbB2tg model we identified a unique multi-protein signaling pathway 
that supports a cardioprotective role of ErbB2 in reducing ROS levels in the heart. It is 
possible that ErbB2 inhibitors can effectively block these components that are necessary 
for preventing adverse cardiac outcomes. The ErbB2tg mouse model is a valuable tool for 
the discovery of novel mechanisms and signaling pathways that have potential 
translational significance for cardiovascular studies and cancer biology. 
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1.1 Epidermal growth factor receptor family 
 The epidermal growth factor (EGF) was initially discovered in 1962 by Stanley 
Cohen, who was later awarded the 1986 Nobel Prize in Physiology or Medicine 1, 2 along 
with his colleague Rita Levi-Montalcini, who was credited with Cohen for their joint 
discovery of the nerve growth factor (NGF) protein 2. More than two decades following 
Cohen’s seminal discovery, EGFR was identified to contain similar peptides and amino 
acid sequences as the avian erythroblastosis tumor virus that is encoded by the v-ErbB-B 
oncogene, for which the ErbB notation is derived 3. The ErbB family of receptor tyrosine 
kinases (RTKs) consists of four members: EGFR, ErbB2 (Her2/neu), ErbB3, and ErbB44, 
5. ErbB1 is known to bind to six ligands: EGF, transforming growth factor alpha (TGF-
α), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, epiregulin, and β-
cellulin 4, 5. A variety of ligands are known to bind to their corresponding ErbB receptor, 
such as neuregulins that preferentially bind to ErbB3 and ErbB4. ErbB2, however, has no 
known soluble ligand but may become activated in the presence of another ErbB 
receptor-ligand complex4, 5. The shared structural features of the ErbBs include cysteine-
rich moieties in the extracellular region and tyrosine autophosphorylation sites in the 
carboxy-terminal tail that is proximal to the kinase domain 5.  
An essential element of the ErbB signaling pathway is the different receptor 
dimers that may form; 10 possible receptor combinations exist among the four ErbB 
receptors4, 5. Since ErbB2 lacks an endogenous ligand, it is the preferred co-receptor for 
the remaining three receptors 6-9. As a consequence for the preferential binding to ErbB2, 
signaling from heterodimer complexes that contain ErbB2 is augmented and stronger 
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than homodimers. Possible reasons for the potency in ErbB2 signaling include reduced 
ligand dissociation from the paired receptor and decreased ErbB2 endocytosis 4.   
 Signaling pathways that are activated by ErbB receptors can be described in terms 
of the input (i.e. ligands) and the ensuing output from the formation of ligand-receptor 
hetero- or homodimers 5. The downstream and intermediate signaling components of 
these ErbB-driven pathways consist of a wide array of kinases. Examples of these include 
the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), and 
protein kinase B (Akt) pathways 5. Further downstream of the ErbB signaling cascade are 
various transcription factors that are necessary for regulating gene expression. 
Accordingly, these genes are translated into proteins that comprise the output: apoptosis, 
cell migration, growth, cell adhesion, and differentiation 5.   
 The role of the ErbB signaling pathways in normal physiological functions is 
illustrated in Fig. 1-1 4. While dysregulated ErbB signaling pathways are implicated in 
the enhancement of mitogenic and transforming potential, the ErbB proteins are 
especially important for organogenesis and differentiation of various cell types, such as 
Schwann cells and oligodendrocytes 4. As shown in Fig. 1-1 the ErbB receptors have 
important physiological roles in the mammary gland, heart, brain, and in Schwann cell 
development. Section 1.1.3 will provide a more detailed discussion on ErbB proteins—
particularly ErbB2—and their role in cardiac development. 
1.2 Characterization of ErbB2 
The protooncogene ErbB2/Her2/Neu encodes the 185 kDa ErbB2 receptor 
tyrosine kinase that localizes to the plasma membrane, nucleus, and mitochondria10. 
Among the family of four ErbB proteins, ErbB2 is the only receptor that lacks a soluble 
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ligand. However, ErbB2 is the preferred heterodimerization partner of EGFR, ErbB3, and 
ErbB4 and is therefore known for its signaling potency as a co-receptor. 
Heterodimerization with ErbB2 results in autophosphorylation of tyrosine residues on the 
ErbB2 receptor. The different components of the ErbB2 receptor are illustrated in Fig. 1-
2. Of particular importance is the extracellular domain (ECD) that is proteolytically 
cleaved in ErbB2-overexpressing breast cancers11-14. The shedding of the ECD renders 
the truncated ErbB2 protein to become more active and increases its kinase activity 11.  
1.3 Importance of ErbB2 in the heart  
 The overexpression of ErbB2 has been implicated in several types of cancer such 
as ovarian and breast due to its enhanced mitogenicity resulting from dysregulated ErbB2 
signaling15-18. Among all of the cancer types, ErbB2-overexpressing breast cancer is the 
most widely studied. An estimated 15-20% of invasive ductal breast cancers occur as a 
consequence of ErbB2 gene amplification that confers a proliferative potential for tumor 
cells and is correlated with a poor clinical outcome19, 20. 
Initial efforts to characterize the functional and physiological significance of 
ErbB2 led to the discovery that genetic deletion of ErbB2 is deleterious for neural and 
cardiac development 21. The findings from this particular study published in 1995 by K.F. 
Lee et al. show that neural deficits in ErbB2 null mice were observed as early as E10.5 at 
the level of the cranial neural-crest-derived neurons, suggesting an important role of 
ErbB2 in neural development 21. In addition to the deleterious effects on neurogenesis, 
the investigators noted that embryos lacking ErbB2 did not survive beyond E11, 
potentially as a result of impaired cardiac development. Indeed, the mutant embryos 
failed to form ventricular trabeculae that are necessary for maintaining blood flow during 
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the early stages of heart development 21. Interestingly, mice that are deficient in 
neuregulin display similar cranial and cardiac phenotypes as ErbB2 null mice, while 
ErbB4 mutant mice, similar to ErbB2, do not survive past E10.5 due to the absence of 
cardiac trabeculae 22-24. Subsequent studies using a cardiomyocyte-specific conditional 
ErbB2 mutant show that ErbB2 mutant mice display impaired cardiac function 
postnatally that is characteristic of dilated cardiomyopathy25, 26. The significance of these 
findings is that ErbB2 is essential for the normal function of the adult heart and drugs that 
inhibit ErbB2, such as Trastuzumab/Herceptin, may prevent cardioprotective ErbB2 
signaling. Taken together, these studies provide substantial evidence for the crucial role 
of the ErbB receptors in cardiac function and development 27. 
The mechanisms that are responsible for the deleterious effects on the heart from 
ErbB2 inhibition have been investigated in various in vitro and in vivo models 28-31 . 
These studies demonstrate that when ErbB2 is inhibited in the cardiomyocyte, apoptosis 
occurs through mitochondrial- and reactive oxygen species (ROS)-dependent pathways. 
For example, neonatal rat ventricular myocytes (NRVM) that are treated with an anti-
ErbB2 antibody express more of the pro-apoptotic Bcl-xS protein and have less Bcl-xL 
protein that promotes cell survival30. A shift towards Bcl-xS has also been observed in 
left ventricular tissues from heart failure patients with a concurrent downregulation of 
both ErbB2 and ErbB4 mRNA and protein 32. Inhibition of ErbB2 in NRVM reduces the 
mitochondrial membrane potential () and adenosine triphosphate (ATP) content, 
suggesting that mitochondrial dysfunction is a consequence of ErbB2 inhibition28, 30. 
Furthermore, increased ROS production is thought to accompany mitochondrial 
impairments that precede cellular death. Conversely, ErbB2-overexpressing mice have 
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increased levels of the pro-survival Bcl2 and Bcl-xL proteins and decreased expression of 
Bcl-xS protein33. The cardioprotective role of ErbB2 is supported by additional studies 
where cardiomyocytes treated with neuregulin-1β (NRG-1β; ErbB4 ligand for which 
ErbB2 is a co-receptor) have upregulated antioxidant mRNA and proteins 34. In a separate 
study, adult rat ventricular cardiomyocytes (AVRM) treated with NRG-1 are protected 
against doxorubicin-induced oxidant stress and have increased mRNA for glutathione 
reductase 35. Thus, multiple models of ErbB2 ablation and overexpression in the heart 
provide potential mechanistic insight on how pharmacological inhibitors of ErbB2 are 










Fig. 1-1. The four ErbB proteins have important physiological functions in 
organogenesis and cellular differentiation. Coordination between the ErbB receptors 











Fig. 1-2.  Schematic of the ErbB2 receptor and the various proteins (i.e. SH2-
substrates) that can interact with the tyrosine moieties for subsequent activation of 
signal transduction pathways. ECD, extracellular domain; TMD, transmembrane 
domain; TKD, tyrosine-kinase domain; ICRD, intracellular regulatory domain; Y, 
phosphotyrosine residues; Grb, growth factor receptor-bound protein; Shk, SH2 domain-























1.4 Clinical problem: synergistic cardiac toxicity from doxorubicin and trastuzumab 
(Herceptin/anti-ErbB2) to treat ErbB2 over-expressing cancers 
 In 1998, trastuzumab/Herceptin was approved by the Food and Drug 
Administration (FDA) to treat ErbB2-overexpressing metastatic breast cancer 2. The 
efficacy of the drug is attributed to its mechanism of action as a recombinant monoclonal 
antibody that targets receptor tyrosine kinase signaling. Discovered by researchers at 
Genentech, trastuzumab is considered the first therapeutic RTK inhibitor that was 
developed through a genomic-based approach 2. When administered with the 
anthracycline doxorubicin to treat ErbB2-overexpressing breast cancer, patients who 
received the combination therapy experienced an increase in time to both disease 
progression and treatment failure and an overall improved response compared to either 
drug alone 36 . Despite the enhanced efficacy from the combination drug therapy, adverse 
cardiotoxic effects occurred in a subgroup of patients36. A retrospective analysis of data 
from patients involved in the trastuzumab clinical trials reveal a higher incidence of 
cardiotoxicity and heart failure in patients who received the combination therapy, thus 
prompting further studies to investigate the underlying mechanism for this cardiotoxicity 
36, 37. Presently, the mechanism for trastuzumab-induced cardiotoxicity is unknown; 
however, varying explanations for the drug-induced cardiotoxicity include altered cellular 
structure, oxidative stress, and changes to calcium homeostasis in cardiac myocytes 37. In 
a separate study that utilized radiolabeled trastuzumab to identify the uptake of the drug 
into the myocardium and tumor, the investigators found myocardial uptake in those 
patients with cardiotoxicity 38. These studies suggest that individuals expressing cardiac 
ErbB2 may be susceptible to adverse cardiac outcomes to trastuzumab.  
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1.5 Doxorubicin induces ErbB2 protein in the heart 
 Anthracyclines such as doxorubicin are known for their chemotherapeutic value 
but have the undesirable effect of causing cardiotoxicity. As described in the preceding 
section, combined treatment of doxorubicin with Herceptin is more efficacious against 
the treatment of cancer; however, this drug therapy combination may lead to cardiac 
dysfunction. Although the underlying mechanism for this cardiac toxicity is poorly 
understood, there is strong support that targeting ErbB2, particularly in the heart, is 
detrimental to cardiac function and development. Thus, while it has been shown that 
cardiomyocytes lacking ErbB2 have greater sensitivity to doxorubicin 39, other studies 
investigated the effects of doxorubicin on ErbB2 expression in the heart 40. In these 
studies, rats were administered a specified cumulative dose of doxorubicin over several 
weeks 40. Cardiac function of the animals was assessed via echocardiography for changes 
in cardiac parameters such as contractility and fractional shortening. Doxorubicin 
treatment reduced both parameters in a dose-response manner; the decrease in 
contractility was accompanied with an increase in the number of TUNNEL-positive 
staining cells and nuclei that are indicative of cellular death 40. Another important finding 
from the study is that doxorubicin induces ErbB2 protein levels and additional proteins 
that are activated downstream of the ErbB2 signaling pathway40. Taken together, these 
findings provide a possible mechanism for the combined drug cardiotoxicity of 
doxorubicin and Herceptin, whereby ErbB2 protein induced by doxorubicin increases the 
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 The essential role of ErbB2 in cardiac function and development is characterized 
in various studies that describe adverse cardiac effects as one of the major consequences 
of attenuated ErbB2 signaling. The importance of ErbB2 in the heart is further 
highlighted in cancer studies in which the incidence of cardiotoxicity is increased when 
patients with ErbB2-overexpressing breast cancer are treated with a combination drug 
therapy consisting of doxorubicin and the monoclonal antibody trastuzumab/Herceptin 
that directly targets ErbB2.  
Though numerous studies have explored ErbB2 inhibition in the heart and 
cardiomyocytes, the consequences of cardiac ErbB2 overexpression are not fully 
understood. Thus, two lines of transgenic mice were developed that over-express ErbB2 
in the heart. The most striking phenotype that the transgenic animals develop is a 
concentric cardiac hypertrophy with an absence of heart failure and no effect on life span. 
Compared to wild type mice, the ErbB2 transgenic animals have larger cardiomyocytes, 
enlarged nuclei, and myocardial disarray. Additional cardiac features of the transgenic 
mice assessed via echocardiography show similar characteristics as observed in patients 
with hypertrophic cardiomyopathy (HCM). Furthermore, cardiac ErbB2 overexpression 
activates signaling proteins that are involved in the ErbB2 pathway, such as EGFR, 
ErbB3, ErbB4, PI3K subunits, and phosphorylated AKT. The hypertrophic phenotype is 
further supported by the upregulation of proteins involved in translation, while the shift 
towards the anti-apoptotic Bcl2 and Bcl-Xl proteins supports the role of ErbB2 in 
cardioprotection. Lastly, the Erb1/2 inhibitor, lapatinib, reduces the heart weights of the 
transgenic animals and inactivates the hypertrophic signaling. To our knowledge, this is 
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the first ErbB2 transgenic model to demonstrate that chronically over-expressed cardiac 
ErbB2 activates protective signaling pathways and induces hypertrophy that has shared 
features with HCM models.  
2.2 Introduction 
 As described in section 1.1.1 of the first chapter, the normal physiological role of 
the ErbB family of RTKs is for cellular differentiation and organogenesis. For example, 
ErbB2 is critical for cardiac function and development. However, dysregulated ErbB2 
signaling is implicated in cancer for its mitogenic potential. In the case of ErbB2-
overexpressing breast cancer, a poor clinical outcome is often a consequence of the 
enhanced proliferative capacity of the tumor cells. Drugs such as Herceptin are effective 
for treating ErbB2-overexpressing breast cancer and its efficacy increases when it is 
combined with the anthracycline doxorubicin. However, as previously discussed in 
section 1.2 the incidence of cardiotoxicity increases when both drugs are administered, 
prompting further studies on the adverse effects from this cancer treatment regimen. In 
order to investigate the role of uninhibited ErbB2 in vivo, we generated two lines of 
transgenic mice with cardiac-specific ErbB2 overexpression. The transgenic construct 
includes the alpha-myosin heavy chain (αMHC) located in the promoter region that 
confers cardiac-specific ErbB2 overexpression. Two founder mice were identified via 
Southern Blotting to contain the ErbB2 transgene; these animals were subsequently used 
to generate two separate lines of ErbB2 transgenic breeding colonies. 
The most striking phenotype of the ErbB2 transgenic mice is a markedly enlarged 
heart, as evidenced by hematoxylin-eosin (H&E) stained transverse cross sections and an 
enlargement of the atria and ventricles compared to the wild type hearts (data not shown). 
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M-mode echocardiography confirmed the presence of concentric hypertrophy, whereby 
the heart walls are hypertrophied and the left ventricular chamber is reduced in the 
transgenic hearts. Additional echocardiographic studies (e.g. left ventricle wall thickness 
and mass) to assess cardiac function confirm the concentric hypertrophy phenotype.  
A possible consequence of cardiac hypertrophy is cardiac dysfunction that can 
lead to heart failure. Despite the observed hypertrophic phenotype, there is an absence of 
heart failure in the transgenic animals. For example, the fractional shortening, which is a 
measure of left ventricle systolic function (represented by the following equation: 
(LVEDd-LVESd)/LVEDd)) x100%), is within the range of normal cardiac function. 
Further support for the lack of heart failure is seen in immunoblots that show a shift 
towards the anti-apoptotic, pro-survival Bcl-xL and Bcl-2 proteins (data not shown). As 
discussed in section 1.1.3, the levels of pro-apoptotic proteins such as Bcl-xS are known 
to increase during heart failure and when ErbB2 is inhibited. 
 Additional studies with the ErbB2 inhibitor lapatinib provide additional evidence 
for ErbB2 and its induction of hypertrophy. In these studies, mice at P4.5 (postnatal day 
4.5) and P10.5 were administered lapatinib via oral gavage. In both cases, the heart 
weights of the transgenic animals were reduced and less ErbB2 protein was expressed 
with lapatinib treatment (data not shown). Thus, the lapatinib studies support the role of 
ErbB2 in cardiac hypertrophy and show that hypertrophy was reversed in younger and 
older animals.  
2.3 Results and Discussion 
 
 The difference in heart weight between the wild type and transgenic mice was 
detected as early as P9.5 (Fig. 2-1) and the difference remains when heart weight is 
15 
 
normalized to body weight (Fig. 2-2). These results suggest that the hypertrophic 
phenotype from overexpressed cardiac ErbB2 may begin after P6.5 and can be reversed 
with lapatinib treatment as shown in Fig. 2-1 and 2-2. Subsequent studies to further 
characterize the ErbB2 transgenic mouse model confirm the presence of concentric 
hypertrophy with features that are consistent with those observed in HCM patients. These 
features include cardiomyocyte hypertrophy, myocardial disarray, and interstitial fibrosis. 
Thus, our model of cardiac ErbB2 overexpression can be a potentially used as a model 
for human HCM. 
 The most significant finding from the cardiac ErbB2 overexpression animal 
model is the distinctive concentric hypertrophic phenotype that does not progress to heart 
failure. Furthermore, signaling pathways that are known to be involved downstream of 
ErbB2, particularly in cancer etiology, are activated such as proteins that regulate 
translation and anti-apoptotic processes that potentially mediate the occurrence of 
hypertrophy. To our knowledge, the ErbB2 transgenic model provides the first evidence 
that ErbB2 overexpression induces the protein expression of the remaining three ErbB 
members and the PI3K-110 and -85 subunits. Our transgenic model provides further 
insight on the functional importance of ErbB2 in the heart, as the mechanisms that 
underlie cardiac ErbB2 induction are currently unknown. Conversely, the studies on the 
implications for ablated and inhibited cardiac ErbB2 highlight the crucial role of ErbB2 
in cardiac function and development. Thus, our ErbB2 transgenic model provides new 
insight on ErbB2 and cardiac hypertrophy that is potentially useful for understanding the 
functional significance of ErbB2 protein in the human heart. 
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 Overexpression of cardiac ErbB2 leads to additional cardiac features that we 
observed through histological staining and electrophysiological studies. For example, 
Masson’s Trichrome stained heart tissue revealed the presence of an age-related 
interstitial fibrosis in the ErbB2 transgenic mice. Heart sections stained with hematoxylin 
and eosin (H&E) show that the ErbB2 transgenic mice have myocardial disarray that is a 
common morphological feature of HCM. Transgenic mice that were treated with 
isoproterenol, a non-specific beta-adrenergic agonist, respond similarly as other HCM 
animal models. Additional electrophysiological studies indicate that the ErbB2 transgenic 
mice have shared features with HCM patients that include an increased sensitivity to 
adrenergic stimulation and arrhythmias.  
 The role of ErbB2 in cardiac hypertrophy was further investigated in studies with 
the EGFR/ErbB2 kinase inhibitor lapatinib. Transgenic mice that were administered 
lapatinib had reduced heart weight/body weights and lowered expression of proteins 
involved in translation. These studies may be useful to identify the underlying 
mechanisms of hypertrophy and additional mechanisms that are relevant to ErbB2 
signaling. 
 In summary, the ErbB2 transgenic model may further our understanding of why a 
subgroup of patients with ErbB2-over-expressing breast cancer are more vulnerable to 
cardiac toxicity from the cancer therapies Herceptin and doxorubicin. It is possible that in 
patients with varying degrees of cardiac hypertrophy where ErbB2 is involved, inhibiting 
ErbB2 activity (such as in cancer therapy) may lead to heart failure. Therefore, the ErbB2 
transgenic model can be used to explore other research avenues for the critical role of 





Fig. 2-1. Heart and body weights of wild type (WT) and ErbB2 transgenic (TG) mice 
at various postnatal (P) ages. The heart weights of the TG mice begin to increase after 









Fig. 2-2. Heart weight normalized to body weight of the WT and TG hearts at 
various postnatal ages. The ratios of heart weight to body weight indicate that the 






















2.4 Methods and Materials 
Animals 
This study was performed in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol was approved by the Committee on the Ethics of Animal Experiments of the 
Johns Hopkins Medical Institutions (Animal Welfare Assurance # A-3273-01). 
Measurement of neonatal heart and body weights 
Wild type and ErbB2 transgenic mice were euthanized and weighed at P3.5, 6.5, and 9.5 
(postnatal days) through decapitation. The hearts were excised and weighed; hearts were 
snap frozen and saved for additional studies. The heart weight/body weight was 
subsequently determined for all three age groups.  
Statistical Methods 
GraphPad Prism software (GraphPad, La Jolla, CA) was used to perform statistical 
analysis. After determining means and standard deviations, the Student unpaired T-test 
was used to determine significance of differences between groups, with a p-value of 

























Overexpression of Epidermal Growth Factor Receptor 2 (ErbB2) in the Heart 

















Cardiac-specific overexpression of epidermal growth factor receptor 2 (ErbB2) in 
mice activates signaling pathways that induce hypertrophy without progression to heart 
failure. However, the transition from hypertrophy to heart failure is mediated by 
oxidative stress. Furthermore, in other models of cardiac hypertrophy with an absence of 
heart failure, glutathione peroxidase (GPx) is activated as a cardioprotective response. In 
order to further understand the lack of heart failure protective phenomenon, we 
investigated whether ErbB2 transgenic (ErbB2tg) mice have increased antioxidant 
protection against reactive oxygen species (ROS). Our results indicate that there is less 
ROS in the hearts and cardiac mitochondria from the ErbB2tg mice. We hypothesized that 
the cardiac protection afforded in the ErbB2tg mice is due to the Abelson 41 nonreceptor 
tyrosine kinases (nRTKs) c-Abl and Arg (Abelson-related gene) that in cancer studies are 
downstream of ErbB2 and in other studies are known to activate GPx. Both nRTK 
proteins were upregulated in the ErbB2tg hearts and co-immunoprecipitation assays show 
that c-Abl and Arg form a complex with ErbB2 protein. To our knowledge, these are the 
first studies to demonstrate ErbB2-Abl kinase protein interaction in the heart. ErbB2tg 
mice have significantly increased levels of glutathione peroxidases (GPx) 1, 3, and 4 
proteins and elevated GPx activity. Treatment with lapatinib (ErbB2/EGFR kinase 
inhibitor) reduced c-Abl and Arg protein expression and subsequent GPx activity. We 
established an in vitro model of ErbB2 overexpression and performed a siRNA-mediated 
targeted knockdown of ErbB2 using H9c2 cells to further investigate an ErbB2-
dependent mechanism for protection against oxidative stress and cellular death, 
particularly against doxorubicin. Overexpression of ErbB2 in H9c2 cells results in 
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increased protection against doxorubicin-induced oxidative stress and cellular death; 
abrogation of ErbB2 reduces the protective effects against doxorubicin. GPx activity was 
found to be independent of ErbB2 signaling in the H9c2 model of ErbB2 overexpression 
and knockdown. However, preliminary studies with neonatal mouse cardiomyocytes 
revealed that GPx activity is higher in the ErbB2tg mouse hearts, suggesting a 
requirement for the hypertrophic phenotype and that the neonatal cardiomyocytes are the 
more appropriate in vitro model four our studies compared to the H9c2 cells. Our results 
demonstrate that the hypertrophic phenotype activates GPx to reduce ROS as a potential 
cardioprotective mechanism to prevent the progression from hypertrophy to heart failure 
in the ErbB2tg mice. We propose a novel multi-protein connection whereby ErbB2/EGFR 
drives GPx activation through c-Abl and Arg to attenuate oxidant stress. Thus, cardiac 
ErbB2 is essential for maintaining antioxidant defenses that protect against oxidative 
damage and heart failure. Lastly, anti-ErbB2 and anti-nRTK drugs may adversely affect 
the redox signaling pathways that are necessary for maintaining anti-oxidant defenses in 
cardiac hypertrophy and potentially in other cells that are dependent on these pathways. 
3.2 Introduction 
In the previous chapter, the phenotypic changes that resulted from the selective 
overexpression of ErbB2 in the cardiomyocyte were described. Among the changes that 
occurred as a result of chronically overexpressed ErbB2 is a distinctive cardiac 
hypertrophy that does not progress to heart failure. The ErbB2 transgenic murine model 
is particularly useful for cardiac studies as ErbB2 knockout mice die prematurely, thus 
precluding the study of specific mechanisms of cardiac protection. The lack of heart 
failure phenotype in the ErbB2tg mice led us to hypothesize that ErbB2 may induce the 
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up-regulation of protective antioxidant enzymes, as previously seen in vitro with 
cardiomyocytes that were treated with neuregulin-1β (NRG-1), a ligand for ErbB4 and a 
hetero-dimerization partner of ErbB2 34, 35. Most importantly, however, is that the 
transition from hypertrophy to heart failure is mediated by oxidative stress 42, 43, 
prompting us to further investigate whether ErbB2 overexpression enhances the 
antioxidant capacity in the heart to subsequently reduce oxidant stress.  
Several studies have shown that glutathione peroxidase (GPx) activity is elevated 
in chronic cardiac hypertrophy and is reduced in heart failure 44-46. Additionally, there is 
evidence to suggest that EGFR (ErbB receptor that is up-regulated by ErbB2 in the 
transgenic mice 33) mediates GPx activity in order to reduce ROS levels 47; however, the 
role of ErbB2 was not investigated. Support for the possible involvement of GPx in the 
ErbB2tg mice is based on microarray data in which the GPx1 and GPx3 genes are 
upregulated as indicated by the z ratios (calculated from the z scores for individual genes 
shown in Fig. 3-2 48) for oxidative stress genes shown in Fig. 3-1. We performed 
quantitative real-time polymerase chain reaction (qRT-PCR) with cDNA from the hearts 
of ErbB2tg and wild type mice to validate the microarray data (Fig. 3-3). Although the 
differences in mRNA were not statistically significant for either gene, the data provided a 
rationale for us to further explore a potential protective role of GPx in the hearts of the 
ErbB2tg mice.  
In order to investigate the mechanism for the protective effects of ErbB2 
overexpression, particularly against ROS and cellular death, we over-expressed ErbB2 in 
vitro and genetically knocked down ErbB2 via siRNA in H9c2 rat cardiomyoblast cells. 
Preliminary experiments using neonatal cardiomyocytes that were isolated from wild type 
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and ErbB2tg hearts allowed us to examine whether the hypertrophic phenotype is 
necessary to regulate GPx activity in the ErbB2tg mice.  Thus, these in vitro models were 
employed to facilitate our understanding of a potential antioxidant-signaling pathway that 












Fig. 3-1. Microarray data of oxidative stress genes suggest that ErbB2 
overexpression results in the upregulation of glutathione peroxidases 1 and 3 (GPx1 
and GPx3).  A heat map of oxidative stress genes sorted from the microarray data that 
were based on the Z ratio that was calculated from the Z scores (n=3 per group). Scale of 





Fig. 3-2. Z scores obtained from individual samples. The Z scores displayed in the heat 
map were used to calculate the Z ratio of the individual oxidative stress genes (n=3 per 











Fig. 3-3. Validation of GPx1 and GPx3 from the microarray data. Quantitative real-
time reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis of Gpx1 and 
Gpx3 do not show any differences in mRNA expression (n=8 per group). Values are 












3.3 Results  
3.1 ErbB2tg hearts have lower levels of ROS 
In vitro studies have shown that ErbB2 pathway activation in adult rat 
cardiomyocytes treated with neuregulin-1β causes an up-regulation of antioxidants 49 and 
protection against oxidative stress 35. Results from analyses that utilized the oxidative 
stress fluorescent indicator 2,7-dichlorodihydrofluorescein diacetate (DCF-DA) and 
electron paramagnetic resonance (EPR) with left ventricular homogenates ( Fig. 3-4 A, 
B) show that the ErbB2tg hearts produce less oxidative stress and superoxide (O2-), 
respectively, compared to WT hearts. Since the mitochondria are important producers of 
ROS 50-52, we measured hydrogen peroxide (H2O2) production in mitochondria using an 
Amplex Red assay. Isolated heart mitochondria from the ErbB2tg hearts release less H2O2 
than WT heart mitochondria (Fig. 3-4 C). Further experiments to assess protein 
carbonylation as a marker of oxidative damage in whole heart lysates did not show any 
differences between both groups of animals (Fig. 3-4 D). 
3.2 ErbB2 overexpression up-regulates nonreceptor tyrosine kinases (nRTKs) c-Abl and 
Arg that are important in glutathione peroxidase activation 
A possible mechanism for ErbB2 signaling that leads to GPx activation may be 
through the nRTKs c-Abl and Arg. First, in vitro studies have shown that GPx activity is 
regulated by c-Abl and Arg 53.  Secondly, in separate studies ErbB2 is known to activate 
and bind to c-Abl and Arg in cancer cells, thus providing further support for the potential 
role of these nRTKs as signaling intermediates for the downstream activation of GPx in 
the ErbB2tg hearts 54, 55. To our knowledge, there are no studies that link ErbB2 to the up-
regulation of nRTK with subsequent GPx activation. Immunoblots and densitometry 
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analysis of phosphorylated and total c-Abl indicate that the transgenic hearts express 
more of these proteins than the wild type hearts (Fig. 3-5 A). Phosphorylation at the 
tyrosine 245 moiety located in the kinase domain of c-Abl contributes to c-Abl kinase 
activation56. Immunoprecipitation results show that c-Abl binds to ErbB2 in the 
transgenic hearts; the interaction between c-Abl and ErbB2 has been shown previously in 
cancer cells 54, 55 but not in the heart (Fig. 3-5 B). Our previous studies on ErbB2 
overexpression in the heart showed a concurrent up-regulation of EGFR 33, an ErbB 
family receptor that is increased when ErbB2 is elevated in cancer cells 57, 58. 
Furthermore, EGFR binds to and activates Abl kinases in breast cancer cells 55. Separate 
in vitro studies have shown that activated Abl kinases phosphorylate EGFR and prevent 
ligand-dependent internalization of the receptor59. Our immunoblotting results show that 
c-Abl binds to EGFR as well as ErbB2 (Fig. 3-5 B). An additional nRTK, Arg, is also 
elevated under the control of ErbB2 in the heart (Fig. 3-5 C) and an immunoblot from an 
immunoprecipitation assay shows that Arg protein also binds to ErbB2 protein in the 
transgenic hearts (Fig. 3-5 D). Total GPx activity in whole heart lysates and in isolated 
heart mitochondria from WT and ErbB2tg mice were measured and GPx activity was 
increased in the ErbB2tg hearts (Fig. 3-5 E, F). The redox- cycling of GPx to remove 
H2O2 requires glutathione (GSH). Our results indicate that the levels of GSH were not 
different between the two groups of animals (Fig. 3-5 G). Since glutathione peroxidases 
can exert cardioprotection 60-62, this enzyme may be involved in pro-survival pathways in 
vivo under the control of ErbB2 protein expression 33. Glutathione peroxidases (GPx) 1, 
3, and 4, in particular, are known to exert antioxidant cardioprotective effects 63 and have 
been shown to be important in cardiac hypertrophy 64, 65. Immunoblotting results (Fig. 3-5 
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H) to assess GPx1 protein expression indicate that the ErbB2tg hearts express GPx1 at a 
significantly higher level than WT hearts. Cytosolic and mitochondrial fractions prepared 
from the hearts of both WT and ErbB2tg animals were probed for GPx1 and immunoblots 
(Fig. 3-5 I) show that GPx1 protein is highly expressed in both the cytoplasm and 
mitochondria of the ErbB2tg hearts compared to the WT hearts. The protein levels of two 
additional glutathione peroxidases, the extracellular GPx3 and GPx4, a phospholipid 
hydroperoxidase, are also elevated in ErbB2tg hearts compared to WT hearts (Fig. 3-5 J, 
K).  
3.3 Lapatinib treatment reduces the expression of the Abl kinases and GPx activity. 
 
In order to determine if ErbB2/EGFR kinase signaling is important for the 
activation of glutathione peroxidases via c-Abl and Arg, eight- to ten-week-old male 
mice were treated with the ErbB2/EGFR inhibitor lapatinib orally for 11 days. Treatment 
with lapatinib reduces both c-Abl and Arg protein expression in ErbB2tg whole heart 
homogenates (Fig. 3-6 A, B). This nRTK reduction was accompanied by a concurrent 
decrease in GPx3 protein and a significant decrease GPx enzyme activity under lapatinib 
treatment (Fig. 3-6 C, E).  
3.4 Overexpression of ErbB2 in the heart increases the levels of p-Src (Tyr416) protein   
A possible signaling intermediate that is downstream of ErbB2 is the non-receptor 
tyrosine kinase Src that has been shown to interact with ErbB2 in breast cancer and 
activates Abl kinases41, 66. The tyrosine 877 (Tyr877) moiety is located in the kinase 
domain of ErbB2 and is homologous to the tyrosine 416 (Tyr416) moiety in the 
activation loop of the Src kinase domain67. Furthermore, phosphorylation at Tyr416 is 
required for Src enzymatic activity67.  
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As expected, the ErbB2tg hearts have higher levels of ErbB2 protein that is 
phosphorylated at Tyr877, rendering an active ErbB2 protein (Fig. 3-7 A). Additionally, 
immunoblots show that the ErbB2tg mouse hearts have an upregulation of p-Src (Tyr416), 
suggesting that Src is in its active form and can subsequently activate the Abl kinases 
(Fig. 3-7 B). 
3.5 Glutathione reductase and thioredoxin reductase activity and protein levels are not 
different in the ErbB2tg mouse hearts 
Since it has been shown that neuregulin-1β treatment up- regulates glutathione 
reductase (GR) mRNA in adult rat ventricular cardiomyocytes 35, we measured GR 
protein expression and activity. The results from the immunoblot and activity assay (Fig. 
3-8 A, C) indicate that there is no difference in GR protein expression or activity between 
WT and ErbB2tg mice. Next, we assessed whether the thioredoxin pathway is involved in 
the redox signaling in ErbB2tg hearts. Thioredoxin reductase 2 (TrxR2) protein and 
activity were measured in whole heart homogenates and mitochondria, respectively, and 
neither was significantly changed in WT and ErbB2tg mice (Fig. 3-8 B, D). 
3.6 H9c2 cells over-expressing ErbB2 are protected against doxorubicin-induced 
oxidative stress and cellular death 
Transient overexpression of ErbB2 in the H9c2 rat cardiomyoblast cell line results 
in a greater than two-fold difference in ErbB2 protein levels compared to the vector 
control (Fig. 3-9 A) and an immunoprecipitation assay indicates that ErbB2 is 
phosphorylated (Fig. 3-9 B). Additionally, ErbB2 overexpression concurrently 
upregulates EGFR protein (Fig. 3-9 C). A widely known consequence for inhibiting 
ErbB2 in the heart is cellular death 28-31. While many studies have shown the deleterious 
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effects from blocking ErbB2, the potential protective effects from ErbB2 overexpression, 
to our knowledge, have not been reported. Our results indicate that ErbB2 is protective 
against oxidative stress from doxorubicin treatment as measured by the DCF-DA 
fluorescent assay (Fig. 3-9 D). H9c2 cells that over-express ErbB2 have more active 
mitochondrial dehydrogenase as assessed by the MTT assay compared to H9c2 cells that 
were transfected with vector (Fig. 3-9 E).  
3.7 siRNA-mediated knockdown of ErbB2 in H9c2 cells reduces the protective effects of 
ErbB2 against oxidative stress and cellular death from doxorubicin 
 Since we showed that ErbB2 overexpression in H9c2 cells is protective against 
doxorubicin-induced oxidative stress and cellular death, we performed a siRNA-mediated 
knockdown of ErbB2 to assess whether the protective effects against doxorubicin would 
become reduced. Our results indicate that transfection with ErbB2 siRNA decreases the 
levels of ErbB2 and EGFR proteins (Fig. 3-10 A, B). Treatment with doxorubicin 
increases ROS levels when siRNA was used against ErbB2 at the highest dose of 
doxorubicin (Fig. 3-10 C). The protective effect against doxorubicin was reduced only at 
the 0.5 µM dose of doxorubicin, suggesting that protection against doxorubicin-induced 
cellular death is not entirely dependent upon ErbB2 at higher doses of doxorubicin (Fig. 
3-10 D). Alternatively, genetically ablated ErbB2 may induce ErbB2 protein upon 
exposure to doxorubicin, as rats treated with doxorubicin had an upregulation of ErbB2 
protein in their hearts40. 
3.8 Overexpression and knockdown of ErbB2 in H9c2 cells does not alter GPx activity 
  As demonstrated by our in vivo findings, GPx protein and activity are increased 
in the ErbB2tg mice. In order to more closely examine whether ErbB2 regulates GPx 
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activity we performed GPx enzymatic assays using H9c2 cells under the conditions of 
ErbB2 overexpression and knockdown. Our results indicate that GPx activity is 
independent of ErbB2 signaling as no change in activity was detected in either group 
(Fig. 3-11 A, B). We proposed that the increase in GPx activity in the ErbB2tg hearts 
occurred as a result of the hypertrophy induced by ErbB2 overexpression. Preliminary 
data show that neonatal cardiomyocytes isolated from the ErbB2tg hearts have higher 
GPx activity compared to WT cardiomyocytes (Fig. 3-11 C). Our results suggest that the 
hypertrophic phenotype is required for regulating GPx activity in the ErbB2tg mice. 
3.4 Discussion 
In our transgenic model of cardiac ErbB2 overexpression the mice develop a 
distinctive hypertrophy that does not progress to heart failure, which is a process that is 
mediated by oxidative stress. The unique phenotype of the ErbB2tg mice prompted us to 
investigate whether ErbB2 upregulation in the heart induces antioxidant defenses against 
ROS. Numerous studies have reported that ErbB2 is essential for protecting against 
cellular death, oxidative stress, and mitochondrial dysfunction28-31; however, the purpose 
of these studies was to address the deleterious effects from ErbB2 inhibition. ErbB2 has 
been connected to antioxidant defense mechanisms in cell culture systems where 
neuregulin-1β (a ligand for ErbB4) treatment upregulates antioxidant enzymes49. This 
signaling likely occurs through either neuregulin-1β-induced hetero-dimerization of 
ErbB2 and ErbB4 or homo-dimerization of ErbB45. The downstream signaling outcomes 
from these receptor pairings—either heterodimers or homodimers—require further study 
but outcomes are likely different5. For example, the receptors themselves when over-
expressed in mice have different phenotypes. Mice over-expressing ErbB4 do not have a 
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hypertrophic phenotype68, 69 whereas ErbB2 over-expressing mice have concentric 
hypertrophy that does not progress to heart failure33.  Thus, the receptors may exert 
distinct control over the signaling to produce hypertrophy outcomes. Neuregulin-induced 
signaling is likely to vary from ErbB2/EGFR collaboration as we demonstrate with our 
findings.   
 We employed three different methods to assess ROS and determined that under 
increased ErbB2 expression, there are lowered levels of ROS in transgenic hearts and 
from isolated transgenic heart mitochondria. Since several studies have shown that GPx 
activity is elevated in chronic cardiac hypertrophy and is reduced in heart failure,44-46 we 
investigated the role of ErbB2 in regulating GPx through c-Abl and Arg, nRTKs that are 
known to be regulated by constitutively active EGFR and ErbB2 in breast cancer cell 
lines55. Additionally, in vitro studies have shown that ErbB2 binds to the SH2 domains of 
Abl kinases as well as phosphorylates c-Abl54. We found that ErbB2 and EGFR are 
associated with c-Abl and that ErbB2 protein binds to Arg in the heart by co-
immunoprecipitation assays. Cardiac ErbB2 overexpression significantly increased levels 
of GPx1, GPx3, and GPx4 proteins, accompanied by an increase in GPx enzymatic 
activity. Next, we found that the ErbB2/EGFR inhibitor lapatinib reduced protein levels 
of both c-Abl and Arg followed by a decrease in the levels of GPx3 protein and GPx 
enzymatic activity, thus supporting the role of ErbB2/EGFR in nRTK pathway activation 
of GPx in the heart. The modest reduction in GPx activity and lack of change in the 
expression of GPx1 and GPx4 proteins with lapatinib treatment may be attributed to the 
length of time that the drug was administered. It is possible that a prolonged treatment 
with lapatinib that exceeds 11 days, as was done for our studies, will reduce all GPx 
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proteins and activity even further. Although ErbB2 has been connected to the activation 
of Src, c-Abl, and Arg in cancer cells 54, 55, 70, and these nRTKs, particularly c-Abl and 
Arg, have been connected to the activation of GPx in various cell lines 53, we are the first 
to show the multiple protein connection between ErbB2/EGFR, Src, c-Abl/Arg, and GPx 
(Fig. 3-12).  
  The role of ErbB2 on initiating EGFR up-regulation was demonstrated in our 
previous studies33 and in multiple cancer models71. The heterodimeric pairing of ErbB2 
and EGFR, for example, prevents EGFR internalization5, 72. Furthermore, Abl kinases 
regulate EGFR receptor internalization59, thus providing additional support for a role of 
Abl kinases in ErbB signaling pathways. While there is evidence for the proximal aspect 
of our proposed mechanism (i.e. ErbB2 to the Abl kinases) and for the distal signaling 
pathway (i.e. Abl kinases to GPx), it is possible that EGFR is similarly involved as ErbB2 
in signaling to Gpx through the Abl kinases. Therefore, a possible limitation of our study 
is that the individual contribution from ErbB2 and EGFR to regulate GPx activity 
through the Abl kinases is not easily distinguishable.    
A possible signaling intermediate that is more immediately downstream of ErbB2 
that activates Abl kinases is the non-receptor tyrosine kinase Src, which is known to 
interact with ErbB2 in various breast cancer cell lines41, 66 and is upregulated in the hearts 
of the ErbB2tg mice. Src activity is required for the phosphorylation of ErbB2 at the 
tyrosine 877 (Tyr877) moiety67. We found that ErbB2 is phosphorylated at Tyr877, 
suggesting that Src is active in the ErbB2tg hearts. Furthermore, the interaction between 
Src and phosphorylated ErbB2 enhances Src activity67. In separate studies we have 
shown through co-immunoprecipitation assays that ErbB2 and Src proteins are bound 
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together in a complex in the ErbB2tg hearts. Active Src in the ErbB2tg hearts, therefore, is 
likely to activate the Abl kinases. To our knowledge, ErbB2 signaling to Src and 
subsequent activation of Abl kinases has not been investigated. Evidence exists, however, 
for activated c-Abl via growth factor stimulation from the plate-derived growth factor 
(PDGF) that is upstream of Src73. Taken together, our results provide support for a 
potential mechanism for ErbB2 signaling to Src that is necessary for Abl kinase 
activation to regulate downstream factors such as glutathione peroxidase74. Additional 
studies are needed to fully characterize this mechanism and to determine whether ErbB2 
is regulating Src and Abl kinases in the heart. For future studies, Src inhibitors may be 
administered to the ErbB2tg mice to assess whether Abl kinase and GPx activity are 
concurrently downregulated in the ErbB2tg hearts. 
In order to strengthen our proposal that ErbB2 is protective against ROS and 
regulates GPx we established in vitro models of ErbB2 overexpression and abrogation 
using the H9c2 rat cardiomyoblast cell line. Under both conditions, the cells were treated 
with doxorubicin75 and ROS production and cellular viability were assessed by DCF-DA 
and MTT assays, respectively. Our results show that ErbB2 overexpression is more 
protective against doxorubicin-induced oxidative stress and cellular death compared to 
vector transfected cells. Genetic knockdown of ErbB2 with siRNA reversed the 
protective effects from ErbB2 against doxorubicin, with increased ROS levels at the 
highest dosage of doxorubicin and a decrease in cellular viability at a lower dosage of 
doxorubicin. Our findings that the protective effects from ErbB2 overexpression against 
doxorubicin are more robust than the changes we observed from ErbB2 knockdown 
suggest that compensatory mechanisms are upregulated when ErbB2 is abrogated. For 
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example, as discussed in Chapter 1, treatment with doxorubicin induces ErbB2 protein in 
rat hearts. Therefore, it is plausible that despite the removal of ErbB2 via siRNA, 
doxorubicin is able to effectively upregulate ErbB2 protein so that the level of ROS 
production and cellular death is close to the levels that were seen in control cells treated 
with doxorubicin. Furthermore, if ErbB2 protein is upregulated by doxorubicin in the 
H9c2 cells as a protective mechanism against oxidative stress and cellular death, then 
ErbB2 overexpression would lead to an additive effect, which we observed in our ErbB2 
overexpression assays. 
Since the ErbB2tg mice have elevated GPx proteins and activity we employed the 
in vitro models to address whether GPx is regulated by ErbB2 signaling. We determined 
that ErbB2 overexpression and knockdown in H9c2 cells does not alter GPx enzymatic 
activity. Though we can conclude from our findings that GPx activation is independent of 
ErbB2, we cannot immediately rule out the possibility that the hypertrophic phenotype is 
necessary for GPx activity in the ErbB2tg mouse model. As previously discussed, GPx 
activity was increased in models of chronic, stable hypertrophy without heart failure44-46. 
Thus, a limitation of the H9c2 in vitro model is that it cannot fully recapitulate the 
phenotypes that occur in vivo and in primary cardiomyocytes. While it has been shown 
that H9c2 cells can be stimulated with endothelin-1 and angiotensin II to acquire 
hypertrophic properties 76, we chose to utilize primary neonatal cardiomyocytes that were 
isolated from wild type and ErbB2tg hearts. Compared to H9c2 cells that have the 
capacity to proliferate, primary neonatal cardiomyocytes are a more relevant in vitro 
model for our studies and can undergo hypertrophy autonomously77, 78. Our preliminary 
studies using pooled neonatal cardiomyocytes from wild type and ErbB2tg hearts indicate 
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that GPx activity is increased in the ErbB2tg cardiomyocytes compared to wild type 
myocytes. Until we confirm our findings with additional animals, our results appear 
promising that the protective antioxidant responses in the ErbB2tg hearts are potentiated 
by ErbB2 signaling and the associated hypertrophy. Thus, further studies are necessary to 
determine whether the distinctive up-regulation and activation of GPx by ErbB2-induced 
signaling may be specifically important in a hypertrophic cardiomyocyte. 
Though we did not observe differences in GPx activity in the H9c2 in vitro 
models, the question remains regarding the protective effects from ErbB2 overexpression 
that are independent of GPx activity. Alternatively, ErbB2 overexpression in H9c2 cells 
may be due to reduced levels of ROS. Possible clues for alternate sources of antioxidant 
protection are from studies where treatment of cardiomyocytes with neuregulin-1β 
induced an increase in gene expression of hypertrophic markers, oxidative stress 
defenses, and pro-survival pathways, similar to the findings of our current study and 
previous studies 33, 49. While other groups found that neuregulin-1β treatment of 
cardiomyocytes increased both glutathione reductase and thioredoxin mRNA and 
proteins 35, 49, this contrasts with our current study, where we found that glutathione 
reducatase (GR) and thioredoxin reductase (TRXR) protein or enzymatic activity are 
unchanged with ErbB2 overexpression in the heart. This suggests that the antioxidant 
defenses induced by an ErbB ligand (neuregulin-1β) versus a receptor up-regulation 
(ErbB2) are similar but not identical and the reasons for this are not known. Activity 
assays for additional redox signaling molecules that function as antioxidants in the H9c2 
in vitro model of ErbB2 overexpression will be performed in future studies. 
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We propose that ErbB2 is an important protein in certain stages of cardiac 
hypertrophy, potentially supporting physiological hypertrophy, while blocking 
pathological hypertrophy. A limitation of our study, similar to other overexpression 
transgenic models, is the increased level of protein expression in cardiomyocytes. 
However, a substantial up-regulation has occurred in mouse models that experience a 
threshold of oxidative stress40 or in stages of heart failure79. Nevertheless, our study in the 
heart is confirmed by other studies in cancer cells and demonstrates that ErbB2 induces 
and activates two classes of protective proteins in the heart: nRTKs and antioxidant 
enzymes. Neonatal cardiomyocytes isolated from wild type and ErbB2tg hearts will be 
used to more closely examine the multi-protein connection between ErbB2, Abl kinases, 
and GPx. For these studies, cardiomyocytes will be treated with imatinib mesylate, a c-
Abl/Arg inhibitor that has been shown to reduce cardiac GPx activity80. We anticipate 
that ErbB2tg cardiomyocytes treated with imatinib mesylate will have reduced GPx 
activity compared to untreated ErbB2tg cardiomyocytes. 
In summary, the heightened antioxidant capacity in the ErbB2tg hearts may be one 
contributing factor supporting the lack of heart failure in this model of hypertrophy. It is 
possible that drug therapies that specifically target ErbB2 are effectively inhibiting the 
antioxidant defenses that are necessary to maintain normal heart function, especially 
under hypertrophic settings and in conditions of oxidative stress. We have shown that 
ErbB2 up-regulates c-Abl and Arg, which are important nRTKs for cardiac growth and 
development81, 82.  In fact, drugs such as imatinib mesylate that target c-Abl/Arg are 
known to cause cardiac dysfunction83-86. Our studies are the first to show that cardiac 
ErbB2 up-regulates and activates GPxs in the heart. We also show that ErbB2 associates 
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with c-Abl and Arg and that the small molecule inhibitor of EGFR/ErbB2, lapatinib, 
reduces levels of c-Abl/Arg with subsequent reduction of GPx enzymatic activity. With 
this heightened GPx antioxidant defense, the ErbB2tg hearts and their mitochondria 
consequently have less ROS. As a proof of principle, our in vitro studies provided 
support for the protective role of ErbB2 against doxorubicin-induced oxidative stress and 
cellular death. Though we did not observe any differences in GPx activity under ErbB2 
overexpression and knockdown in H9c2 cells, we hypothesized that the hypetrophic 
phenotype is required for the increase in GPx activity that occurs in the ErbB2tg hearts. 
Furthermore, primary neonatal cardiomyocytes will serve as the more appropriate model 
over H9c2 cells to assess GPx activity under the control of ErbB2 signaling. Finally, our 
findings suggest that adverse effects on redox signaling pathways that are necessary for 
maintaining antioxidant defenses may be an important mechanism of cardiac toxicity 














Fig. 3-4. ErbB2tg hearts have less oxidative stress and lower levels of O2-. and 
mitochondrial H2O2 compared to wild type hearts. (A) Left ventricular homogenates 
from ErbB2tg hearts have less oxidative stress based on the oxidation of the DCF-DA 
fluorescent indicator of general oxidative stress (n=4 per group). (B) An EPR anaylsis 
using the O2-. -specific probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl 
pyrrolidine (CMH) indicates that the ErbB2tg hearts contain less O2-. (n=3-5 per group). 
(C) Isolated heart mitochondria from ErbB2tg hearts produce less mitochondrial H2O2 
than the wild type hearts as determined by the Amplex Red assay (n=6 per group). (D) 
Representative immunoblot of protein carbonyl levels in total heart lysates do not show 
any differences between both groups (n=6 per group)  *p<0.05. Values represent the 














Fig. 3-5. c-Abl and Arg proteins that are known to regulate glutathione peroxidase 
(GPx) activity are upregulated and co-immunoprecipitate with ErbB2 in the heart. 
Increased levels of GPx 1, 3, and 4 proteins and GPx activity are induced by cardiac 
ErbB2 overexpression. (A) Representative immunoblots show higher expression of 
phosphorylated c-Abl at Tyr245 (p-c-Abl (Tyr245)) and total c-Abl protein in  ErbB2tg 
hearts (n=7 per group). (B) c-Abl was immunoprecipitated from whole heart 
homogenates and co-immunoprecipitated with ErbB2 (n=6 per group) and EGFR (n=2 
per group). (C) Representative immunoblot of Arg shows higher expression of Arg in the 
ErbB2tg hearts compared to the wild type group (n=7 per group). (D) Arg was 
immunoprecipitated from whole heart homogenates and co-immunoprecipitated with 
ErbB2  (n=6 per group). (E-F) Whole heart homogenates (n=4 per group) and 
mitochondria (n=8 per group) isolated from the ErbB2tg hearts have higher GPx activity 
than wild type hearts. (G) Glutathione (GSH) levels are not different between WT and 
TG animals (n=6 per group). (H) Representative immunoblot shows higher expression of 
GPx1 in whole heart homogenates of transgenic hearts compared to wild type hearts 
(n=12 per group). (I) GPx1 is elevated in cytosolic and mitochondrial fractions from 
ErbB2tg  hearts as shown in representative immunblots (n=6 per group). (J) 
Representative immunoblots show higher expression of GPx3 (n=7 per group) and (K) 
GPx4 in transgenic hearts compared to wild type hearts *p<0.05. Values represent the 










Fig. 3-6. ErbB2 and EGFR kinases are responsible for maintaining c-Abl and Arg 
protein levels and GPx activity. (A) Treatment with the ErbB2/EGFR inhibitor lapatinib 
reduces c-Abl protein in transgenic whole heart homogenates (n=6 per group). (B) 
Lapatinib reduces Arg protein in whole heart homogenates from transgenic animals (n=4-
5 per group). (C) GPx activity is reduced by lapatinib in the transgenic animals (n=7 per 
group). (D-F) Immunoblots show that only GPx3 protein is reduced in transgenic animals 
after treatment with lapatinib (n=4 per group).  * p<0.05, veh=vehicle, lapa=lapatinib. 





Fig. 3-7. Expression of p-ErbB2, Src, and p-Src proteins in the ErbB2tg mouse 
hearts. ErbB2tg mouse hearts have higher levels of (A) phosphorylated ErbB2 (p-ErbB2) 
and (B) Src (p-Src) proteins compared to wild type hearts (n=6 and 10 per group, 











Fig. 3-8. Glutathione reductase (GR) and thioredoxin reductase 2 (TRXR2) protein 
levels and activity are unchanged by overexpression of ErbB2 in the heart. (A) GR 
protein levels (n=7 per group) and (C) activity (n=7 per group) are not different between 
the WT and TG hearts. (B) No difference in TRXR2 protein levels (n=5 per group) or (D) 
activity (n=6 per group) was found between both groups of animals. *p<0.05. Values 












Fig. 3-9. ErbB2 overexpression in H9c2 cells protects against doxorubicin-induced 
oxidative stress and cell death. H9c2 cells were transfected with pcDNA (3.1) + vector 
or ErbB2 plasmid. (A) A representative immunoblot shows that transfection with ErbB2 
plasmid increases the levels of total and (B) phosphorylated ErbB2 proteins (n=6 per 
group). (C) ErbB2 transfection in H9c2 cells upregulates EGFR protein as shown by a 
representative immnublot (n=6 per group). (D) After 48 hr of transfection the cells were 
incubated with vehicle or doxorubicin (dox) for 6-24 hr. ROS production was determined 
using the DCF-DA fluorescent assay for general oxidative stress (n=6 per treatment 
group) and (E) cell viability was determined by the MTT assay (n=6 per treatment 
group). *p<0.05. Two-way ANOVA<0.05, *p<0.05 versus vector with 0µM dox, 
#p<0.05 versus ErbB2 with 0µM dox, ┼p<0.05 versus vector with dox dose. Values 











Fig. 3-10.  siRNA-mediated knockdown of ErbB2 in H9c2 cells reduces the 
protective effect against doxorubicin-induced oxidative stress and cell death. (A) 
Transfection with ErbB2 siRNA decreases the levels ErbB2 and (B) EGFR proteins as 
shown by representative immunoblots (n=6 per group). (C) After 48 hr of transfection the 
cells were incubated with vehicle or doxorubicin (dox) for 6-24 hr. ROS production was 
determined using the DCF-DA fluorescent assay for general oxidative stress (n=6 per 
treatment group) and (E) cell viability was determined by the MTT assay (n=6 per 
treatment group). *p<0.05. Two-way ANOVA<0.05, *p<0.05 versus vector with 0µM 
dox, #p<0.05 versus ErbB2 with 0µM dox, ┼p<0.05 versus vector with dox dose. Values 





Fig. 3-11.  GPx activity is not altered with overexpression or knockdown of ErbB2 in 
H9c2 cells. Preliminary data from isolated neonatal cardiomyocytes indicate that the 
ErbB2tg hearts have higher GPx activity compared to wild type cardiomyocytes. (A) 
H9c2 cells transfected with plasmid to overexpress ErbB2 or (B) siRNA to knockdown 
ErbB2 have no effect on GPx activity (n=6 per group). (C) Neonatal cardiomyocytes 
isolated from the ErbB2tg hearts have greater GPx activity than WT cardiomyocytes (n=1 



















Fig. 3-12. Proposed mechanism of ErbB2 signaling through Src and the nonreceptor 















3.5 Methods and Materials 
 
Animals 
This study was performed in strict accordance with the recommendations in the “Guide 
for the Care and Use of Laboratory Animals” (2011) of the National Institutes of Health. 
The protocol was approved by the Animal Care and Use Committee of the Johns Hopkins 
Medical Institutions (Animal Welfare Assurance # A-3273-01). The ErbB2tg and wild 
type 48 mice used in this study were developed as described 33.  
Cell Culture 
The H9c2 rat cardiomyoblast cell line was obtained from ATTC (USA) and maintained 
in DMEM supplemented with 10% foetal bovine serum (FBS) and 1% penicillin-
streptomycin antibiotic at 37ºC and 5% CO2. The cells were subcultured at a ratio of 1:4 
every 3-4 days. 
ErbB2 overexpression and siRNA knockdown of ErbB2 in H9c2 cell line 
H9c2 cells were transfected with rat-neu/ErbB2 or pcDNA 3.1(+) control plasmid DNA 
using the Fugene HD (Promega, Madison, WI) reagent. After 48 hr the cells were 
harvested to obtain lysates for subsequent assays or treated with vehicle/doxorubicin 
(Bedford Laboratories, Bedford, OH) for MTT and DCF assays. For the siRNA 
experiments, ON-TARGET plus Rat ErbB2 (24337; Thermo Scientific, Waltham, MA) 
siRNA with the targeting sequences GGUAGACGCUGAAGAGUAU and 
GACAGAAGAUCCGGAAGUA were used at 25nM. 
Treatment of H9c2 cells with doxorubicin 
Dosages for doxorubicin were determined according to published studies of doxorubicin-
treated H9c2 cells75. For ErbB2 overexpression and knockdown studies, doxorubicin was 
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added to the H9c2 cells at 24 and 48hr-post transfection. Assays for oxidative stress and 
cellular viability were performed 6-24hr after drug treatment. 
Isolation of neonatal cardiomyocytes 
Wild type and ErbB2tg neonate mice between the ages of one- to two-days-old were used 
for cardiomyocyte isolations87. Briefly, the mice were euthanized via decapitation and the 
hearts were immediately removed and rinsed in HBSS without Ca2+ and Mg2+ (Life 
Technologies, Grand Island, NY), minced, and enzymatically dissociated in 0.25% 
trypsin (Life Technologies, Grand Island, NY) containing HBSS without Ca2+ and Mg2+. 
The supernatant containing the cells was collected and HBSS with Ca2+ and Mg2+ was 
added. After the tissue was dissociated, the cells were collected and resuspended in 
complete MEM (Life Technologies, Grand Island, NY) media containing 20% FBS, 
100U/ml penicillin, and 100µg/ml streptomycin. The cells were pre-plated for 2hrs to 
exclude non-muscle cells and plated at the appropriate cell density.  
Microarray Analysis of Wild Type and Transgenic Mice 
Total RNA was extracted from the hearts of the WT and ErbB2 TG mice (3 mice per 
genotype) 33for whole genome expression analysis using an Illumina Bead Array. 
Microarray data were analyzed using a spreadsheet-based microarray analysis program 
(DIANE 6.0) and the oxidative stress genes were analyzed by cluster analysis to 
determine the patterns of expression between ErbB2 TG mice and WT mice. Genes were 
determined to be differentially expressed based on the z-ratio (Z ratio > 1.5), false 





Real-time PCR and Primers Design 
Total RNA was isolated from the hearts of the WT and ErbB2 TG mice (8 mice per 
genotype) as described 33. Glutathione peroxidase 1 (Gpx1) and glutathione peroxidase 3 
(Gpx3) were chosen from the microarray data of statistically significantly up-regulated 
oxidative stress genes and were evaluated by quantitative real-time reverse transcriptase-
polymerase chain reaction (qRT-PCR). The primer pairs for mouse Gpx1 were as 
follows: 5’-CGGGGCAAGGTGCTGCTCAT-3’ forward and 5’- 
GCACGGGAAACCGAGCACCA-3’ reverse. The primer pairs for mouse Gpx3 were as 
follows: 5’-CATCCTGCCTTCTGTCCCTG-3’ forward and 5’-
GTTGGAAGGGAAGCCCAGAA-3’ reverse. Peptidylprolylisomerase A (PPIA) was 
used for RNA normalization. The qRT-PCR results were calculated by delta-delta Ct 
method using the mean of the delta Ct value of wild type mice as a normalization factor. 
Immunoblotting 
Transfected H9c2 cells were washed with cold 1X PBS and harvested in 1X PBS with a 
cell scraper and centrifuged. Lysis buffer (25 mM Na2HPO4, 25 mM NaH2PO4, 150 mM 
NaCl, 10% glycerol, 1 mM EDTA) was added to the cell pellet and spun down. The final 
supernatant contained the soluble protein used for standard gel electrophoresis and 
immunoblotting33. 
Both WT and TG hearts were evaluated by Western blotting for protein expression. 
Frozen left ventricle (40 mg) was rapidly homogenized in 200–300 µL of lysis buffer (25 
mM Na2HPO4, 25 mM NaH2PO4, 150 mM NaCl, 10% glycerol, 1 mM EDTA) and 
standard gel electrophoresis and immunoblotting were performed33. The primary 
antibodies used were directed against GPx1, GPx3, GR (Abcam, Cambridge, 
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Massachusetts), GPx4 (Cayman Chemical, Ann Arbor, MI), Akt, c-Abl, p-c-Abl 
(Tyr245), p-ErbB2 (Tyr877), p-Src (Tyr416), Src (Cell Signaling, Danvers, MA), ErbB2, 
EGFR, TrxR2, Prohibitin, GAPDH (Santa Cruz, Santa Cruz, CA), and Arg (US 
Biological, Salem, MA). After incubation in anti-rabbit, -mouse, or -goat (GE Healthcare, 
Piscataway, NJ and Santa Cruz Biotechnology, Santa Cruz, CA) horseradish peroxidase-
linked secondary antibody, blots were exposed to chemiluminescent substrate (Pierce, 
Rockford, IL) and exposed to CL-Xposure film (Pierce, Rockford, IL). Levels of Akt33 
and GAPDH proteins were measured to normalize protein quantities across samples. 
Immunoprecipitation 
Lysates from H9c2 cells and heart tissue were prepared for immunoprecipitation as 
described 33. Briefly, cell lysates were incubated with anti-ErbB2 antibody (Santa Cruz, 
Santa Cruz, CA), anti-Src antibody (Cell Signaling, Danvers, MA), anti-c-Abl antibody 
(Santa Cruz, Santa Cruz, CA), or Arg antibody (US Biological, Salem, MA) at 4°C 
overnight (3 µg of antibody per 1000 µg of total protein). Protein A or G beads (GE 
Healthcare Life Sciences, Pittsburgh, PA) were washed with cold lysis buffer and 
centrifuged (3,000 RPM for 1 min). Tissue lysates were incubated with anti-c-Abl 
antibody (Santa Cruz, Santa Cruz, CA) or Arg antibody (US Biological, Salem, MA) at 
4°C overnight (3 µg of antibody per 1000 µg of total protein). Protein A or G beads (GE 
Healthcare Life Sciences, Pittsburgh, PA) were washed with cold lysis buffer and 
centrifuged (3,000 RPM for 1 min). The buffer was aspirated and the beads were added 
to the antibody-treated lysates and incubated at 4°C overnight. The beads were washed 
three times and centrifuged at 3,000 RPM for 1 minute. The supernatant was discarded 
and urea buffer with beta-mercaptoethanol (BME) was added to the beads. The 
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suspension was heated at 95°C for 5 minutes and centrifuged at 3,000 RPM for 1 minute. 
The supernatant was loaded on a SDS gel and the immunoblotting protocol was followed 
as described above. The membranes were probed with phospho-tyrosine (Cell Signaling, 
Danvers, MA) or anti-ErbB2 antibody (Santa Cruz, Santa Cruz, CA). 
Mitochondrial Isolation from Hearts 
Mitochondria were isolated from hearts as described in88. Briefly, hearts were excised 
from TG and WT mice and placed in mitochondrial isolation buffer (10 mM Hepes, 0.25 
M Sucrose, 1 mM EGTA) to remove excess blood from the hearts as described88. The 
hearts were cut into small pieces and then placed in a 30 ml homogenizer with 0.7 
mg/mL (per mouse heart) Nagarse, Protease Type XXIV from Bacillus licheniformis 
(Sigma-Aldrich, St. Louis, MO) in 1 ml of mitochondrial isolation buffer. The tissue was 
homogenized for approximately eight minutes, transferred to a 1.5 mL microcentrifuge 
tube and centrifuged at 8,500 x g for eight minutes. The supernatant containing the 
protease was removed immediately and the remaining pellet was homogenized in fresh 
mitochondrial isolation buffer without the protease. The contents were transferred to 1.5 
mL micocentrifuge tubes and a series of differential centrifugations at 4°C were 
performed to isolate the heart mitochondria and remove excess cellular components and 
tissue debris 88. The final mitochondrial pellet was re-suspended in the mitochondrial 
resuspension buffer (10 mM Hepes, 0.25 M Sucrose, 0.1% BSA) and protease inhibitors 
(Roche Applied Science, Indianapolis, IN) and phosphatase inhibitor cocktails 2 and 3 





Reactive Oxygen Species Measurements 
The formation of ROS in heart homogenates and transfected H9c2 cells (1.2 x 104 cells 
per well in a 96-well plate) was measured using the 2,7-dichlorodihydrofluorescein 
diacetate (DCF-DA, Sigma-Aldrich, St. Louis, MO) general oxidative stress fluorescent 
indicator. For heart homogenates, 1μM of DCF-DA was incubated with 200μg of heart 
homogenate and fluorescence was recorded over 1hr at an excitation of 485 nm and 522 
nm emission89. Measurements of ROS in H9c2 cells were performed with 50µM DCF-
DA that was prepared in clear DMEM and added to each well for 30 min at 37ºC in the 
dark. An initial reading was taken at an excitation of 485 nm and 522 nm emission. The 
DCF-DA was removed and vehicle or doxorubicin was added to each well. Readings 
were taken at an excitation of 485 nm and 522 nm emission every hour for up to 6 hr 
followed by a 24 hr reading. The Amplex Red assay (Invitrogen, Carlsbad, CA) was used 
to measure hydrogen peroxide (H2O2) produced from the isolated heart mitochondria. 
The mitochondria were energized with succinate 90, 91 and H2O2 production was measured 
in both unstimulated (-ADP) and stimulated (+ADP) states. For preparation of tissue for 
electron paramagnetic resonance spectroscopy (EPR), ventricles were homogenized in 
lysis buffer (12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 75 mM NaCl, 10% glycerol, 0.5 
mM EDTA, 1:100 of phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich, St. Louis, 
MO), one tablet of complete mini, EDTA-free protease inhibitor (Roche Applied Science, 
Indianapolis, IN)) and centrifuged at 21,000 x g for 10 minutes. Stock solutions of 1-
hydroxy-3- methoxycarbonyl-2,2,5,5- tetramethylpyrrolidine (10mM CMH, Enzo Life 
Sciences, Farmingdale, NY) were made in nitrogen purged 0.9% (w/v) NaCl, 25g/L 
Chelex 100 (Bio-Rad) and 0.1mM DTPA 92. 70 µg of protein were combined with the 
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CMH probe (1mM). Samples were assayed in 50 µL glass capillary tubes at room 
temperature using the Bruker E-scan EPR spectrometer (Bruker, Billerica, MA). 
Spectrometer settings were as follows: sweep width: 100G; microwave frequency: 9.75 
GHz; modulation amplitude: 1 G; conversion time: 5.12ms; time constant: 5.12ms; 
receiver gain, 2×102; number of scans, 4. Relative superoxide levels were assessed by 
measuring the signal amplitude.  
Measurement of Oxidized Proteins 
Protein carbonyl levels were measured in lysates from left ventricular tissue using the 
OxyBlot Protein Oxidation Detection Kit (Millipore, Billerica, MA) according to the 
manufacturer’s protocol. Briefly, 20 µg of protein were derivatized to 2, 4-
dinitrophenylhydrazone (DNP-hydrazone) with 2, 4-dinitrophenylhydrazine (DNPH). 
The protein samples were separated on a SDS gel using the immunoblotting protocol as 
described above. The membrane was probed with rabbit anti-DNP antibody (provided in 
the kit) and the blots were subsequently processed based on the immunoblotting 
instructions described above.     
MTT Assay 
Cell viability was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT) assay whereby cells with an active mitochondrial 
dehydrogenase convert MTT to an insoluble purple formazan. Briefly, transfected H9c2 
cells (1.2 x 104 cells per well in a 96-well plate) were exposed to vehicle or doxorubicin 
with or without 5mM N-acetylcysteine (NAC, Sigma-Aldrich, St. Louis, MO) for 6 hr. 
The media was aspirated and 100 µl of 5 mg/ml MTT reagent in PBS was added to each 
60 
 
well at 37ºC for 4 hr. The insoluble purple formazan was dissolved in 100 µl of dimethyl 
sulfoxide and the absorbance was read at 570 nm on a microplate reader. 
Lapatinib Treatment 
Wild type or ErbB2tg male mice were treated with oral lapatinib (160 mg/kg) daily 93, 94. 
24G-20 gavage needles (Braintree Scientific, Inc., Braintree, MA) were used. Lapatinib 
(LC Laboratories, Woburn, MA) suspension was made fresh before each treatment. 
Lapatinib was diluted with buffer containing 0.5% carboxymethyl cellulose, 1.8% 
sodium chloride, and 0.4%Tween-80 in deionized water (dH2O). Because a percentage of 
unmetabolized lapatinib is excreted with feces, mice were housed in separate cages 
(vehicle or lapatinib group). Animals were treated daily for 11 days and then euthanized 
2 hours after the final treatment. Hearts were excised, weighed, and tibia length 
measured. Hearts were sectioned and the left ventricle frozen for further molecular 
studies. 
Glutathione Peroxidase (GPx) Activity Assay 
GPx activity was measured with a NADPH-linked enzymatic assay to monitor the 
decrease in NADPH absorbance at 340 nm. Reagents were obtained from the GPx 
activity assay kits ADI-900-158 (Enzo Life Sciences, Plymouth Meeting, PA) and GPx 
Assay Kit 703102 (Cayman Chemical, Ann Arbor, MI). Lysates from transfected H9c2 
cells were washed with cold 1X PBS and harvested in 1X PBS with a cell scraper and 
centrifuged. Lysis buffer (25 mM Na2HPO4, 25 mM NaH2PO4, 150 mM NaCl, 10% 
glycerol, 1 mM EDTA) was added to the cell pellet and spun down. Hearts from WT and 
TG mice were homogenized in cold assay buffer containing 0.4 mM PMSF, protease 
inhibitors, and 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) and the homogenate 
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was centrifuged at 10,000 x g for 10 minutes at 4°C. The supernatant was collected and 
diluted in assay buffer. Mitochondria were isolated as described above and were similarly 
diluted in the GPx assay buffer. 
Quantification of Glutathione 
Glutathione was quantified as described 95 with slight modifications using a Bioxytech 
GSH/GSSG-412 kit (Oxis Research, Portland, OR). Hearts were homogenized in six 
volumes of 5% metaphosphoric acid and 5.6 µl of the supernatant were added to 394.4 µl 
of assay buffer (100 mmol/l NaPO4, 5 mmol/l EDTA, pH 7.5). After the addition of 5,5’-
dithiobis-(2-nitrobenzoic acid) (DTNB) and glutathione reductase the samples were 
incubated for five minutes at room temperature. NADPH was added to the samples and 
the absorbance was recorded at 412 nm for three minutes.  
Glutathione Reductase (GR) Activity Assay 
GR activity was measured by the rate of NADPH oxidation at an absorbance of 340 nm. 
Reagents were obtained from a GR activity assay kit 703202 (Cayman Chemical 
Company, Ann Arbor, MI). Hearts from TG and WT mice were homogenized in cold 
buffer containing 50 mM potassium phosphate, 1 mM EDTA and the homogenate was 
centrifuged at 10,000 x g for 15 minutes at 4°C. The supernatant was collected and 
diluted in assay buffer containing 50 mM potassium phosphate, 1 mM EDTA, and 1 
mg/ml BSA. 
Thioredoxin Reductase 2 (TrxR2) Activity Assay 
Mitochondria were isolated from the hearts of WT and TG mice. Prior to the assay, the 
mitochondrial membranes were removed by a series of freeze-thaw cycles between dry 
ice and ethanol at 37°C. After the membranes were removed, the mitochondria 
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preparation was centrifuged for two minutes at 20,000 x g and the supernatant was 
collected for use in the assay. The samples were prepared in a master mix containing 
5mM DTNB, 8% ethanol, 300 µM NADPH, and PE buffer (100 mM potassium 
phosphate, 2 mM EDTA, pH 7.0). TrxR2 activity was measured by the reduction of 
DTNB by TrxR2 and NADPH at an absorbance of 412 nm. 
Statistical Methods 
GraphPad Prism software (GraphPad, La Jolla, CA) was used to perform statistical 
analysis.  After determining means and standard deviations, the Student unpaired T-test 
was used to determine significance of differences between groups. Two-way analysis of 
variance (ANOVA) and Tukey’s post hoc tests were performed for multiple comparisons. 


























































 The rationale for studying the ErbB2tg heart mitochondria was based on 
microarray analyses that revealed a subset of genes involved in complex I of the electron 
transport chain were downregulated in the hearts of the ErbB2tg mice. Since 
mitochondrial alterations have been implicated in cardiac hypertrophy it was plausible 
that overexpression of ErbB2 in the heart would modulate mitochondrial function in 
response to hypertrophy. We probed for key factors involved in mitochondrial biogenesis 
and found that the levels of protein in the ErbB2tg hearts were unaffected by ErbB2 
overexpression. Next, we performed functional studies with isolated heart mitochondria 
and determined that mitochondrial oxygen consumption with complex I and II substrates 
was not different in the ErbB2tg heart mitochondria compared to wild type mitochondria. 
Complex I enzymatic activity of the ErbB2tg heart mitochondria was similarly unaffected 
by ErbB2 overexpression. The discordancy between the microarray data and our 
mitochondrial studies requires further investigation. A known consequence of cardiac 
hypertrophy is altered ATP production. We measured ATP production with 
mitochondrial substrates for complex I, II, and IV and found that the mitochondria from 
the ErbB2tg hearts did not have reduced ATP production compared to wild type heart 
mitochondria. Further characterizations of the mitochondria involved measuring the 
mitochondrial membrane potential () with the tetramethylrhodamine ethyl ester 
(TMRE) fluorescent indicator. Our studies indicated that mitochondria from the ErbB2tg 
hearts have a higher baseline  that was supported with additional assays from neonatal 
cardiomyocytes that had higher staining with a JC-1 dye that accumulates in polarized 
mitochondria. Since the  is a marker of cellular viability, our findings support the pro-
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survival phenotype that is characteristic of the ErbB2tg mouse model. However, 
additional mechanisms that may influence the  in the ErbB2tg mice have yet to be 
elucidated. Lastly, we measured the calcium (Ca2+) retention capacity of the 
mitochondria and found that mitochondria from the ErbB2tg hearts have less Ca2+ uptake 
compared to wild type heart mitochondria. Though the implications for these findings are 
currently unknown and require further investigation, we have found that ErbB2tg hearts 
have higher baseline Ca2+ transients and faster Ca2+ reuptake. Studies to characterize the 
ErbB2tg heart mitochondria are far from complete; however, our findings, particularly 
from the  and Ca2+ assays provide a basis for exploring the mitochondria further in 
order to gain a better understanding for how ErbB2 regulates mitochondrial function in 
cases of hypertrophy without progression to heart failure. 
4.2 Introduction 
 Initial microarray studies that compared differentially expressed genes between 
the wild type and ErbB2 transgenic mice revealed possible mitochondrial dysfunction 
caused by cardiac ErbB2 overexpression. Though the microarray analysis required 
further validation, it was possible that the ErbB2-induced hypertrophic phenotype altered 
the mitochondria, perhaps as a compensatory response to the hypertrophy. The important 
role of ErbB2 on mitochondrial function has been investigated in cancer biology and in 
various cardiac studies. For example, ErbB2 was found to translocate into the 
mitochondria in order to regulate mitochondrial respiratory functions that are altered in 
cancer cells10. Notably, this particular study provided insight on how mitochondrial 
ErbB2 contributes to chemotherapy resistance (i.e. trastuzumab/Herceptin) and the switch 
from oxidative phosphorylation to aerobic glycolysis—referred to as the Warburg 
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effect—that is advantageous for the survival of the cancer cell10. While the exact 
mechanism for the effects of mitochondrial ErbB2 on cellular metabolism is poorly 
understood, other studies have shown that ErbB2 regulates mitochondrial function 
through uncoupling protein 2 (UCP2) in cancer cells 96. As discussed in section 1.1.3 of 
the first chapter, inhibition of ErbB2 in NRVM results in cellular death through apoptosis 
and ROS that are mediated by a decrease in  and impaired mitochondrial function. 
Collectively, these studies suggest that ErbB2 tyrosine kinase activity is important for 
maintaining the protective cellular adaptations through the mitochondria.  
 While it is known that cardiac hypertrophy alters mitochondrial function, the 
degree of mitochondrial impairment is dependent upon whether the hypertrophy is 
physiological or pathological. In physiological hypertrophy, such as when the heart 
enlarges in response to pregnancy and exercise, the heart has the ability to adapt to the 
increased workload without negatively affecting cardiac function97-100. Conversely, in 
pathological hypertrophy, the negative hypertrophic response can result in contractile 
dysfunction and heart failure98, 101. Since we observed hypertrophy without progression to 
heart failure in the ErbB2 transgenic model, we hypothesized that mitochondria from the 
transgenic hearts would have features that are characteristic of physiological hypertrophy. 
Listed in Table 4-1 are the mitochondrial alterations that have been identified in both 
physiological and pathological hypertrophies and their corresponding stimuli to induce 
hypertrophy 98. Though various signaling transduction pathways have been implicated in 
altering mitochondrial function during physiological and pathological hypertrophies, the 
mechanisms involved in these pathways are not completely understood 98. Interestingly, 
the ErbB2 transgenic mice display a few of the features that are described for 
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pathological hypertrophy, such as fibrosis and upregulated fetal genes that are found in 
the microarray analysis. However, much of the data from the ErbB2 transgenic model 
suggest that the transgenic mice lack many of the characteristics of mitochondrial 
dysfunction that are listed in Table 4-2  98 that are correlated with pathological 
hypertrophy, such as increased ROS. Taken together, our findings support the idea that 
some overlap exists between the pathophysiology of physiological and pathological 
hypertrophy.  
Due to the complexity of the mitochondria, we chose to examine several 
mitochondrial indices that would serve as an initial basis for subsequent, in-depth 
analyses on the effects of ErbB2 overexpression on the mitochondria. We examined 
differences in the expression of mitochondrial biogenesis proteins and measured 
mitochondrial respiratory function with complex I and II substrates of the electron 
transport chain. Additional studies to characterize the mitochondria included 
measurements of ATP,, and calcium retention capacity. Our findings will allow us to 
identify potential novel mechanisms of ErbB2 signaling to the heart mitochondria, 
whereby alterations in mitochondrial function are uniquely regulated by cardiac ErbB2 






Table 4-1. Characteristics of physiological and pathological hypertrophy. The 
hypertrophic stimuli and the corresponding mitochondrial alteration is shown for each 





Table 4-2. Mechanisms of mitochondrial dysfunction in pathological hypertrophy. 















Mitochondrial biogenesis proteins are unchanged by cardiac ErbB2 overexpression 
 The initial efforts to characterize the mitochondria involved an assessment of 
whether key mitochondrial biogenesis proteins were differentially expressed between the 
wild type and ErbB2 transgenic hearts. One of the most important activators of 
mitochondrial biogenesis is the peroxisome proliferator-activated receptor-γ (PPARγ) 
coactivator-1 (PGC-1) family that consists of two members: PGC-1α and PGC-1β 102, 103. 
These proteins function as co-transcriptional regulation factors that stimulate 
mitochondrial biogenesis by activating transcription factors such as the nuclear 
respiratory factors (NRF-1 and NRF-2) that will subsequently induce the expression of 
mitochondrial transcription factor A (Tfam), which is essential for mitochondrial DNA 
(mtDNA) transcription and replication 102, 103. In addition to the NRFs, PGC-1α regulates 
mitochondrial biogenesis via the uncoupling proteins (UCPs) 102, 103. Another key 
regulator of mitochondrial biogenesis that was assessed in our studies is adenosine 
monophosphate-activated protein kinase (AMPK) that functions primarily to regulate 
intracellular energy metabolism, particularly during changes in cellular energetics 102. A 
third mitochondrial biogenesis protein that we measured was the orphan nuclear receptor 
estrogen-related receptor α (ERRα) that is activated by PGC-1α in order to regulate the 
expression of genes involved in oxidative phosphorylation and mitochondrial biogenesis 
102-104. Lastly, we probed for PPARα, a nuclear receptor that is coactivated by PGC-1 and 
has been implicated in both mitochondrial biogenesis and fatty acid oxidation 102, 103. The 
immunoblots for the mitochondrial biogenesis proteins show that the levels of the 
proteins are not expressed differently between the wild type and ErbB2 transgenic hearts 
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(Figure 4.3.A). Our findings suggest that cardiac ErbB2 overexpression does not seem to 
alter the expression of key mitochondrial biogenesis proteins. 
Mitochondrial oxygen consumption and complex I activity are not different between the 
wild type and ErbB2 transgenic mitochondria 
 The evidence for the presence of mitochondrial perturbations as a consequence of 
cardiac ErbB2 overexpression was from a subset of microarray data that indicated a 
group of complex I genes were downregulated in the ErbB2 transgenic hearts. In order to 
address whether complex I was dysfunctional in the transgenic hearts, we isolated cardiac 
mitochondria and performed mitochondrial respiratory function studies using complex I 
substrates glutamate and malate. The respiratory control ratio (RCR) was calculated as 
the ratio of state 3 to state 4 respirations and is an important determinant of mitochondrial 
function and integrity. The data show that the cardiac mitochondria from both groups of 
animals have similar RCR values; furthermore, the RCR values that we obtained are 
within the range of RCR values that have been reported for mitochondria isolated from 
mouse hearts (4.3.B (A)). The amount of oxygen consumed under state 4 (oxygen 
consumed on complex I substrates) and state 3 respiration (oxygen consumed during the 
conversion of ADP to ATP) conditions are also similar between the wild type and ErbB2 
transgenic mitochondria (4.3.B (B)). Next, we assessed complex I activity and did not 
find any differences between both groups of animals (4.3.B (C)). We measured 
respiratory function with succinate, a complex II substrate and observed a lower RCR for 
the transgenic mitochondria; however, the difference was not statistically significant 
(4.3.B (D)). The state 3 and state 4 respirations were also not different between the two 
groups of animals (4.3.B (E)). Collectively, our results indicate that the ErB2 transgenic 
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cardiac mitochondria are not dysfunctional at the level of complex I, suggesting that 
cardiac ErbB2 overexpression does not compromise the mitochondria at this region of the 
electron transport chain.   
ATP generated from complex I, II, and IV substrates are not different between the wild 
type and ErbB2 transgenic mitochondria  
 One of the most essential functions of the mitochondria is to produce ATP that is 
necessary for the overall health and survival of the cell. Measurements of ATP generation 
are typically performed to identify mitochondrial impairments that may be linked to a 
defective electron transport chain or to oxidative stress. Using isolated cardiac 
mitochondria, we performed a luminescence assay to determine the amount of ATP in the 
presence of complex I, II, and IV substrates. As expected, the concentration of ATP that 
is produced decreases as electrons move progressively down the electron transport chain 
starting from complex I, as shown in Figure 4.3.C. Furthermore, we did not observe any 
differences in the amount of ATP between the wild type and ErbB2 transgenic 
mitochondria. 
ErbB2 transgenic mitochondria have a higher baseline mitochondrial membrane 
potential () than wild type mitochondria 
 The  is an important component of the proton motive force that is necessary for 
oxidative phosphorylation and ATP generation. Measurements of  have been utilized 
as a marker for cellular viability, ROS emission, and mitochondrial indices such as 
mitochondrial dysfunction and apoptotic signaling105-107. For our studies, we quantified 
the  using the  
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TMRE cationic fluorescent dye under nonquenching conditions108  in the presence of 
glutamate and malate. Prior to the addition of ADP, the TMRE fluorescence from the 
ErbB2 transgenic mitochondria at 20 minutes was higher than the fluorescence emitted 
from the wild type mitochondria (4.3.D). Upon the addition of ADP to stimulate state 3 
respiration at 30 minutes, the TMRE fluorescence remained higher in the transgenic 
mitochondria compared to the wild type mitochondria and persisted until the uncoupler 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP) was added to completely dissipate 
the  (4.3.D). Further support for our findings is from neonatal cardiomyocytes that 
were stained with the membrane-permeant JC-1 dye that accumulates in polarized 
mitochondria, resulting in a fluorescent emission from green to red (data not shown). In 
depolarized mitochondria, however, the JC-1 dye fails to become sequestered into the 
mitochondria and the red to green fluorescence intensity decreases. Thus, our results 
indicate that the ErbB2 transgenic mitochondria maintain a higher baseline  compared 
to the wild type mitochondria.  
ErbB2 transgenic mitochondria have less calcium (Ca2+) uptake compared to the wild 
type mitochondria 
 Calcium handling in the cell is intricately linked to mitochondrial processes such 
as ATP generation and ROS production 105. For example, mitochondrial Ca2+ uptake via 
the Ca2+ uniporter (MCU) is regulated by the  in order to stimulate the tricarboxylic 
acid (TCA) cycle, resulting in activation of the electron transport chain and oxidative 
phosphorylation to ultimately generate ATP 105, 109. Several hypotheses exist that Ca2+ 
stimulates the production of mitochondrial ROS from various locations of the electron 
transport chain 105. However, the exact mechanism for Ca2+-induced mitochondrial ROS 
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production is still under investigation. For our studies, we measured the Ca2+ retention 
capacity of the mitochondria isolated from the wild type and ErbB2 transgenic hearts. 
Using the fluorescent probe Calcium Green-5N110  to measure extramitochondrial Ca2+, 
we determined that the ErbB2 transgenic mitochondria require less pulses of Ca2+ 
compared to the wild type mitochondria in order to reach a point of saturation, whereby 
the fluorescent intensity is at a maximum (4.3.E). The representative curves that are 
displayed in Figure 4.3.E show that over a period of one hour the wild type mitochondria 
have a greater capacity to uptake and release Ca2+ compared to the ErbB2 transgenic 
mitochondria. Our results suggest that the ErbB2 transgenic mitochondria have less 
mitochondrial Ca2+ uptake due to altered mechanisms for Ca2+ entry, such as through the 
MCU or the other modes of Ca2+ uptake that consists of the rapid-mode Ca2+ uptake 
(RaM) and the ryanodine receptor (RyR) 105, 109. Another plausible explanation is that the 
ErbB2 mitochondria are in a swollen state thereby preventing Ca2+ from either entering or 





Fig. 4-1. Expression of key mitochondrial biogenesis proteins. Immunoblots show that 
the levels of various mitochondrial biogenesis proteins are not different between the wild 














Fig. 4-2. Mitochondrial respiration studies with substrates for complex I and II 
indicate that respiratory function of isolated mitochondria from the ErbB2 
transgenic hearts is not different compared to wild type. (A) The respiratory control 
ratio (RCR; state 3/state 4) is an index of the integrity of the isolated mitochondria; 
results show that the RCR (B) state 4 and state 3 respiratory rates (n=8 per group) and (C) 
complex I enzyme activity are similar between both groups of animals (n=6 per group). 
(D) Respiratory assays with the complex II substrate succinate indicate that the (D) RCR 
and (E) state 3 and state 4 respiratory rates are not different between both groups of 






Fig. 4-3. ATP production from isolated heart mitochondria is similar between both 
groups of animals. The decrease in ATP production with substrates for complex I, II, 

















Fig. 4-4. Mitochondria isolated from the ErbB2tg hearts have a higher mitochondrial 
membrane potential () compared to wild type heart mitochondria. The  was 
assessed in a nonquenching mode whereby depolarized mitochondria accumulate less of 
the cationic Tetramethylrhodamine, Ethyl Ester, Perchlorate (TMRE) dye compared to 
hyperpolarized mitochondria that will have a higher TMRE fluorescence due to a greater 
concentration of TMRE in the mitochondria. The  for each group was quantified based 
on the average TMRE fluorescence that is represented by the curves in the bottom graph 
(n=3 per group). The bar graph (top) was generated from the corresponding TMRE 
fluorescent values that are shown in the curves. After 20 and 30 minutes the  was 
higher in the ErbB2tg heart mitochondria compared to mitochondria isolated from the 














Fig. 4-5. The ErbB2tg mitochondria have less Ca2+ uptake compared to wild type 
mitochondria. Representative curves of the wild type and ErbB2tg mitochondria are 
shown in the top graph, which indicates that the wild type mitochondria require more 
pulses of Ca2+ as indicated by the arrows. The number of Ca2+ pulses quantified for each 

















































 The high demand that is imposed upon the heart to produce ATP through 
oxidative metabolism necessitates the large density of mitochondria that are contained in 
cardiac myocytes. Moreover, the importance of cardiac mitochondria in heart function 
requires that these organelles have the ability to adapt to changes in the energy 
requirements of the cell. In the case of cardiac hypertrophy that is induced by increased 
workload such as during exercise, the mitochondria respond to the energetic demands by 
proliferating and producing sufficient amounts of ATP 98. If, however, the hypertrophy 
becomes decompensated, mitochondrial dysfunction ensues that may ultimately lead to 
heart failure 98. In our model of cardiac ErbB2 overexpression we observed a striking 
hypertrophic phenotype without progression to heart failure. Our findings coupled with 
microarray data to suggest that mitochondrial complex I genes were downregulated led us 
to further investigate the effects from ErbB2 overexpression on the mitochondria. We 
probed for proteins that are critical for mitochondrial biogenesis and can be altered in 
hypertrophy. Our results indicate that the expression of PGC-1, AMPK, ERR, and 
PPAR proteins is not different between the wild type and ErbB2 transgenic hearts. 
Thus, cardiac ErbB2 overexpression and the resulting hypertrophy do not perturb the 
protein levels of key mitochondrial biogenesis factors. Further support for our findings is 
from electron microscopy images of ErbB2 transgenic mitochondria that appear to have 
normal morphology (data not shown).  
 Rather than validate the microarray data via qPCR we opted instead to examine 
complex I and II respiratory function and complex I activity. Our results show that there 
are no differences in the RCR or state 3 and state 4 respiration with complex I and II 
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substrates as well as in complex I activity between both groups of animals. Possible 
explanations for the discrepancies between the microarray data and our mitochondrial 
respiration studies are that the downregulated genes do not affect the translation or 
degradation of the proteins that are necessary for mitochondrial function. Another 
plausible explanation is that the ErbB2 transgenic mitochondria are equipped with 
compensatory mechanisms that can sufficiently overcome any mitochondrial deficits. 
Although we did not observe any mitochondrial dysfunction at the level of complex I and 
II, it is possible that mitochondrial impairments may exist further downstream of the 
electron transport chain. Additional studies are necessary to validate the microarray data 
and to more accurately assess mitochondrial function with different mitochondrial 
respiratory chain substrates. 
 A known consequence of mitochondrial dysfunction and hypertrophy is impaired 
ATP production98, 111. We determined that the ErbB2 transgenic mitochondria do not 
produce less ATP with complex I, II, and IV substrates compared to wild type 
mitochondria.  Reduced ATP production occurs during decompensated, pathological 
hypertrophy that is a contributing factor for the onset of heart failure 98. Thus, our 
findings provide additional insight on whether ErbB2 overexpression induces a 
physiological or compensated form of hypertrophy. 
 One of the most interesting findings from the mitochondrial characterization 
studies were from the  assays where we showed through two different methods—
TMRE fluorescence and JC-1 staining of neonatal mouse cardiomyocytes—that the 
ErbB2 transgenic hearts have a higher  compared to wild type hearts. Since the  is 
an important indicator of cellular viability, the higher  in the transgenic hearts supports 
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our previous findings that the pro-survival, anti-apoptotic proteins Bcl2 and Bcl-xL are 
increased in the transgenic hearts. For example, it has been hypothesized that an increase 
in  may serve as an adaptive response against apoptosis, particularly in the transition 
from compensated hypertrophy to heart failure 112. While our  data support the anti-
apoptotic phenotype from cardiac ErbB2 overexpression, the high  suggests that the 
transgenic hearts would have more ROS production and oxidative stress rather than less, 
which we have shown through three different methods in the previous chapter. A possible 
explanation for these disparate results is that the antioxidant capacity in the transgenic 
hearts is elevated under hypertrophy as a protective mechanism against oxidative stress. 
The distinct role of  on ROS regulation warrants further examination, as other groups 
have found that a depolarized  was associated with an increase in ROS production 113.   
 The integral role of Ca2+ in mitochondrial function is to stimulate oxidative 
phosphorylation for ATP synthesis. When Ca2+ homeostasis is disrupted, such as in 
pathological hypertrophy, mitochondrial dysfunction ensues that may accompanied by 
increased ROS and cellular death 105, 114.We measured mitochondrial Ca2+ handling and 
found that the ErbB2 transgenic mitochondria have less Ca2+ uptake compared to the wild 
type mitochondria. The precise mechanism for cardiac ErbB2 overexpression on 
mitochondrial Ca2+ in our transgenic model is poorly understood. Adding to the 
complexity of our mitochondrial Ca2+ findings are studies that link mitochondrial matrix 
Ca2+ ( [Ca2+]m) overload to increased ROS and opening of the permeability transition pore 
resulting in apoptosis115 105. However, we observed less ROS and apoptosis in the ErbB2 
transgenic hearts; further studies are needed to explain the discordancy in our findings. 
Since Ca2+ stimulates the TCA cycle, we cannot rule out the possibility that the reduced 
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uptake of Ca2+ by the ErbB2 transgenic mitochondria is somehow related to TCA cycle 
activation 114. Thus, for future studies, we will measure [Ca2+]m and α-ketoglutarate 
dehydrogenase and pyruvate dehydrogenase enzymatic activities to assess whether 
[Ca2+]m in the ErbB2 transgenic mitochondria is increasing the activity of these enzymes. 
Lastly, we observed in separate studies that the ErbB2 transgenic hearts have higher 
baseline Ca2+ transients and faster Ca2+ reuptake. However, additional studies are needed 
to understand how ErbB2 overexpression regulates Ca2+ in the cardiomyocyte, 
particularly in the cytosol and mitochondria.  
 In summary, our mitochondrial characterization studies provided much-needed 
insight on whether cardiac ErbB2 overexpression and the resulting hypertrophy lead to 
mitochondrial alterations that are characteristic of physiological and pathological 
hypertrophy. Based on our findings, we were able to determine that ErbB2 
overexpression does not affect key mitochondrial biogenesis proteins or respiratory 
function with complex I and II substrates. Furthermore, while we did not observe deficits 
in ATP production, we found that the  is increased and that the transgenic 
mitochondria have less Ca2+ uptake. Although the exact mechanism for ErbB2-induced 
hypertrophy on the  and [Ca2+]m are unknown, our studies may prove useful for 
understanding mitochondrial processes that are regulated by tyrosine kinase signaling and 
hypertrophy, particularly in cases where there is an absence of heart failure.  










The immunblotting protocol that was described in section 3.5 of the previous chapter was 
used but with slight modifications. The primary antibodies used were directed against 
PGC-1 (Santa Cruz, Santa Cruz, CA), AMPKα (cell Signaling, Danvers, MA), ERRα, 
and PPARα (Millipore, Billerica, MA). Levels of GAPDH (Santa Cruz, Santa Cruz, CA) 
protein were measured to normalize protein quantities across samples. 
Mitochondrial Isolation from Hearts 
The protocol for isolating mitochondria from heart tissue was followed as described in 
section 3.5 of the preceding chapter. 
Mitochondrial Respiration Studies 
Respiration was measured using freshly isolated heart mitochondria (200µg of 
mitochondrial protein resuspended in 10mM Hepes, 0.25M Sucrose, 1mM EGTA, 0.1% 
BSA) that was added to a 25°C chamber containing mitochondrial respiration buffer 
(120mM KCl, 1mM EGTA, 5mM MOPS, 5mM K2HPO4, 0.2% BSA). Oxygen 
consumption was monitored with a Clark-type O2 electrode (Instech, Plymouth Meeting, 
PA) connected to an O2 monitor (Model 5300, YSI, Inc., Yellow Springs, OH)116, 117. 
Glutamate/malate (10mM/2mM) or succinate (5mM) was added to the chamber followed 
by ADP (0.5mM) for state 3 respiration. After the ADP was converted to ATP, the state 4 
respiratory rate was measured. 
ATP Measurements 
Isolated heart mitochondria were placed in mitochondrial respiration buffer (120mM 
KCl, 1mM EGTA, 5mM MOPS, 5mM K2HPO4, 0.2% BSA) and incubated with 
glutamate/malate (10mM/2mM), succinate (5mM), or TMPD/ascorbate (0.2mM/5mM) 
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with ADP (0.5mM), oligomycin (1µg/mL), and 2,4-dinitrophenol (DNP, 50µM). The 
samples were centrifuged and the supernatant was collected for ATP measurements using 
the luminescence-based ATP Determination Kit (Molecular Probes, Eugene, OR). 
Briefly, a reaction buffer and stock solutions for D-luciferin and dithiothreitol (DTT) 
were prepared according to the manufacturer’s instructions; a standard reaction solution 
was prepared by combining the components along with firefly luciferase. ATP standard 
solutions were also prepared to generate a standard curve. The standard reaction solution 
was dispensed into each sample well and the luminescence was recorded. 
Measurements of mitochondrial membrane potential () 
The  was measured using a 96-well fluorescent plate reader and 10nM of 
tetramethylrhodamine ethyl ester (TMRE) that was added to the isolated heart 
mitochondria (350µg mitochondrial protein/well) contained in the appropriate buffer 
(135mM KCl, 20 mM MOPS, 5 mM K2HPO4, 5mM MgCl2, pH 7.0)116. The respiratory 
substrates glutamate/malate (10mM/2mM) were added to the mitochondria at the 
beginning of the assay. After approximately 30min ADP (0.5mM) was added to allow 
state 3 respiration to occur. Thirty minutes following the addition of ADP, the uncoupler 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 20µM) was added to dissipate the 
. Fluorescent readings were recorded at an excitation of 544nm and 590nm emission. 
Mitochondrial calcium (Ca2+) retention capacity 
A 96-well fluorescent plate reader and the Calcium Green 5N fluorescent indicator110 
(2µM, Life Technologies, Green Island, NY) were used to measure extramitochondrial 
Ca2+. The mitochondria (300µg) were contained in mitochondrial swelling buffer 
(120mM KCl, 10mM tris-HCl, 5mM MOPS, 5mM KH2PO4, 0.005mM EGTA) and 
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glutamate/malate (10mM/2mM) was used as the respiratory substrates. A stock of CaCl2 
(0.5mM) was prepared in ddH2O and was added for a final concentration of 20µM to 
each well every minute up to 60 min. The fluorescence was recorded at an excitation of 































































5.1 Chronic overexpression of ErbB2 in the heart as a model to study ROS and 
mitochondrial function 
The work that is presented in this dissertation adds to a growing body of research 
that ErbB2 serves a critical role in the heart. Using the ErbB2tg mouse model we provide 
evidence for a novel redox signaling pathway regulated by ErbB2 overexpression in the 
heart, whereby Abl kinases are upregulated to activate Gpx in order to reduce ROS 
production. The heightened antioxidant capacity in the ErbB2tg hearts is a likely factor 
(among many that have yet to be discovered) involved in the reduced propensity of the 
hypertrophic transgenic hearts from going into heart failure. Additional studies will be 
performed with neonatal cardiomyocytes isolated from wild type and ErbB2tg hearts to 
confirm our in vivo findings that ErbB2 regulates GPx, particularly under hypertrophy. 
 The mitochondrial studies will serve as a foundation for future research into how 
ErbB2 uniquely regulates mitochondrial function. As we have seen in our work, both the 
 and Ca2+ handling are significantly different compared to wild type heart 
mitochondria. In fact, very preliminary studies that employed sensitive, cuvette-based 
fluorometric techniques confirmed that the  is higher and ROS levels are lower in the 
ErbB2tg heart mitochondria. However, these assays revealed that ubiquinone of complex I 
may be damaged in the wild type mitochondria, suggesting that the mitochondrial 
impairments are strain-specific or that ErbB2 overexpression is activating compensatory 
mechanisms against these mitochondrial deficits. More studies are necessary to carefully 
investigate these findings. 
 The ErbB2tg model continues to offer new and interesting avenues for research 
into signaling pathways that are regulated by ErbB2 overexpression. Though much work 
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is needed to fully understand the complexities of ErbB2 overexpression in the heart, our 
work uncovers novel mechanisms for the protective effects of ErbB2 in heart. Finally, the 
translational significance of these studies will be for the development of drugs that are 
efficacious in cancer therapy but are designed to exclude cardiotoxic effects. 
5.2 Additional studies 
5.2.1 Establishing an in vitro model of ErbB2 overexpression in HEK293 and H9c2 cells 
  
 The plasmids for the pcDNA 3.1(+) vector and R-neu were designed by Dr. Yi 
Xu. The following data are from studies that were performed in order to establish an in 
vitro model of ErbB2 overexpression in HEK293 and H9c2 cell lines. Transfection 
protocols were optimized to ensure that the plasmid delivery and transfection efficiency 












Fig. 5-1. HEK293 cells transiently transfected with the control plasmid (pcDNA) or 
ErbB2-overexpressing plasmid (R-neu). Immunoblotting results show that R-neu-
transfected cells express more ErbB2 compared to vector-transfected cells, with a 
concurrent upregulation of phosphorylated ErbB2 (p-ErbB2 877) and EGFR proteins. 








Fig. 5-2. The H9c2 rat cardiomyoblast cell line was selected for subsequent in vitro 
studies of ErbB2 overexpression and knockdown. Shown here are immunoblots of 
ErbB2 and EGFR proteins based on three different transfection protocols. Four our 
studies, the transfection reagent Fugene HD caused the least amount of cellular death and 










Fig. 5-3. Serum (10% FBS) starvation of transfected H9c2 cells. A series of 
experiments were performed to assess whether serum starvation was necessary for the 
H9c2 transfections. We determined that serum starvation was not needed for 























5.2.2 Overexpression of ErbB2 in HEK293 cells upregulates β2-adrenergic receptor (β2-
AR) 
 
 Recently submitted work that investigated the role of cardiac ErbB2 in β2-AR 
signaling included the following figure that shows immunoblots for ErB2 overexpression 
in HEK293 cells. Most importantly, however, is that ErbB2 overexpression upregulates 

















Fig. 5-4. HEK293 cells transfected with ErbB2 plasmid have a concurrent upregulation 




























5.2.3 Acute treatment with doxorubicin reduces the survival of ErbB2tg mice  
 
In separate studies with doxorubicin, wild type or ErbB2tg mice were 
administered a single dose of 20 mg/kg doxorubicin by intraperitoneal injection. Control 
animals received an equivalent volume of saline.  Mortality was assessed over a four-day 
period after the injections and the surviving animals were euthanized after four days. Our 
results indicate that the ErbB2tg mice have a lower tolerance for doxorubicin, as indicated 












Fig. 5-5. Doxorubicin treatment and survival. Acute treatment with doxorubicin (dox) 
significantly reduced the survival of the transgenic (TG) mice compared to similarly 
treated wild type animals (n=6 per group). For survival statistics Log-rank (Mantel-Cox) 
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